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1. Introduction  
 
 
Heterocyclic chemistry is an inexhaustible resource of novel compounds. 
Almost unlimited combinations of carbon, hydrogen, and heteroatoms can be 
designed, making available compounds with the most diverse physical, chemical, 
and biological properties. Heterocycles provide the main source of new aromatic 
compounds. 
Heterocycles form by far the largest of the classical divisions of organic 
chemistry and are of immense importance biologically, industrially, and indeed to 
the functioning of any developed human society. The majority of pharmaceuticals 
and biologically active agrochemicals are heterocyclic, as are countless additives 
and modifiers used in industries as varied as cosmetics, reprography, information 
storage, and plastics.1  
Among approximately 20 million chemical compounds identified by the end of 
the second millennium, more than two-third are fully or partially aromatic, and 
approximately half are heteroaromatic. Moreover, despite these numbers, known 
or unknown heteropolycycle systems can reveal different kind of properties, 
justifying the interest of the synthetic chemistry for new or differently substituted 
structures. For example, the paper “Heteroaromatic Rings of the Future” 
published by some authors of the University of Cambridge on the Journal of 
Medicinal Chemistry in 2009,2 constitutes a stimulus to creative organic chemists. 
In fact, in this contribution is highlighted a small set of apparently simple, but 
unconquered, ring systems arising from five- and six-membered rings with one or 
more heteroatoms, that are predicted to be suitable in the development of novel 
















































1.1. The importance of heterocyclic chemistry 
 
1.1.1. In biochemistry and life processes 
 
Heterocycles play a major part in biochemical processes. DNA and RNA, the 
essential constituents of living cells, are based on pyrimidine [cytosine (1), uracil 
(2), and thymine (3)] and purine [adenine (4) and guanine (5)] bases (Figure 2), 
which are all aromatic heterocycles. Hydrolyses of DNA and RNA produce five 
nucleosides, 6-10, each being composed of an aromatic heterocyclic base, a 
phosphate, and a ribose moiety (Figure 3); the latter two form the backbones of 
the polymer, and in the DNA’s double helix the C-G and A-T base pairs form the 
rungs of the ladder. The aromaticity, hydrogen-bonding properties, and catalytic 
activity of the pyrimidine and purine bases of RNA may explain why they were 
formed in prebiotic conditions and gave rise to the “RNA world”, which evolved 









































































































6 a: Adenylic acid (R = OH)
   b: Deoxyadenylic acid (R = H)
7 a: Guanylic acid (R = OH)
   b: Deoxyguanylic acid (R = H)
8 a: Cytidylic acid (R = OH)
   b: Deoxycytidylic acid (R = H)
9 Deoxythymidylic acid (R = H) 10 Uridylic acid
 
 
The essential amino acids tryptophan (11) and histidine (12) are aromatic 
heterocycles (Figure 4). They participate along with other amino acids in protein 
constitution through amide linkages. Histamine, formed by decarboxylation of 
histidine, is a powerful vasodilator, is released in allergic responses, and 
stimulates acid secretion in the stomach, causing heartburn. Histidine receptor 
antagonists are among the top pharmaceuticals. Serotonin, formed from 
tryptophan, is an important neurotransmitter. LTyrosine is oxidized biologically to 
L-dihydroxyphenylalanine (L-DOPA); this affords dopamine by decarboxylation, 
and its production may be involved in schizophrenia (dopamine excess) or 
Parkinson’s disease (dopamine deficit, treatable by administering L-DOPA). A 
practically infinite number of proteins can be synthesized from the 20 naturally 
occurring amino acids with the aid of DNA via translation into RNA messenger 





















Tryptophan 11 Histidine 12  
 
 
Most coenzymes have aromatic heterocycles as major constituents. While 
enzymes possess purely protein structures, coenzymes incorporate non-amino 
acid moieties, most of them aromatic nitrogen heterocycles. Coenzymes are 
essential for the redox biochemical transformations, e.g., nicotinamide adenine 
dinucleotide (NAD, 13) and flavin adenine dinucleotide (FAD, 14) (Figure 5). Both 
are hydrogen transporters through their tautomeric forms that allow hydrogen 
uptake at the termini of the quinonoid chain.  
 
 












































13 NAD (R = OH)
     NADPH (R = OPO3H2)
     








Some important vitamins, 16-20, are constructed on an aromatic heterocyclic 







































Folic acid 16 Didydrofolic acid 17 Tetrahydrofolic acid 18
R =
    Vitamin B5 19
Nicotinic acid (R = OH)
Nicotinamide (R = NH2)
    Vitamin B6 20
Pyridoxine (R = CH2OH)
Pyridoxal (R = CHO)
Pyridoxamine (R = CH2NH2)
 
 Porphyrins 21 are the backbone of major players in life cycles-cytochromes 
(Figure 7). There are three types of cytochromes, classified by their color, or 
more precisely by their long-wavelength absorption band, as a (600 mn), b (563 
nm), and c (550 nm). They are protein conjugates of a porphyrin complex with 
iron(II), which is a coenzyme of protein hemoglobin called heme (22). Porphyrin 
derivatives are used in photodynamic therapy for dermatological diseases such 







































Numerous plant and animal hormones have aromatic heterocycles as a major 
component. 
 
1.1.2. In society 
 
Observations of life in nature by primitive communities led humans to the 
discovery of many healing materials. Many pharmaceutical products are mimics 
of natural products with biological activity, which include many heterocycles. In 
the fight against disease, some of the most significant advances have been and 
are being made by designing and testing new structures, many of which are 
heteroaromatic derivatives. The same is true for many pesticides. Antibiotics 
such as penicillins and cephalosporins, alkaloids such as vinblastine, ellipticine, 
morphine, and reserpine, and cardiac glycosides such as the class of digitalis are 
heterocyclic natural products of significance for human and animal health. 
Inspired by them, pharmaceutical researchers have constantly designed and 
produced better pharmaceuticals for a better living. In the same light, pesticides, 
insecticides, rodenticides, and weed killers followed natural models, and a 
significant part of such biologically active compounds are heterocycles. 
 
Modern life and civilization opened the way to other important practical 
applications of heterocycles, for example dyestuffs, copolymers, solvents, 
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photographic sensitizers and developers, and in the rubber industry antioxidants 
and vulcanization accelerators. Some of the sturdiest polymers, such as kevlar, 
have aromatic rings. Melamines (2,4,6-triamino-substituted triazines) are 
monomers with numerous applications as both homopolymers and copolymers. 
Figure 8 shows a few examples of compounds with various applications in our 











































1.1.3. As a fundamental science 
 
Apart from all the above reasons underlying the importance of heterocyclic 
chemistry as an applied science, it has much fascination as a subject for study in 
its own right.4 
 
 
The work accomplished during my thesis deals with the synthesis of different 
fused polyheterocyclic compounds involving the combination of well-established 







1.2. Aim of the thesis work  
The work accomplished in this thesis concerns three different projects to 
achieve fused-ring heteropolicyclic systems having potential pharmacological 
properties. The synthetic procedures employed to reach this goal involve well 
known methodologies based on the functionalization of carbon-carbon double 
bonds. 
 
Results will be presented in three different sections. 
 
The first one deals with diversity-oriented synthesis to access complex 
structures containing a piperidine unit starting from enantiopure 2-allyl-piperidine.  
 
The second section concerns the study of a synthetic protocol for a new class 
of enantiopure tetracyclic 1,4-benzodiazepin-5-ones, containing an imidazole and 
a pyrazole ring.5 
 
Finally, third part is related to the obtainment of bicyclic oxazolidinone 
derivatives by Pd(II)-CuCl2 catalyzed intramolecular reactions on alkoxycarbonyl-




















2. Results and discussion 
 
 
2.1. Enantiopure 2-allyl-piperidine as building blo cks in the 
“diversity-oriented synthesis” of piperidine deriva tives  
 
Piperidine is a heterocyclic ring widespread either in natural compounds or in 
biologically active molecules. The most of natural piperidinyl derivatives are 
mainly present in trees, but can be found also in insects and amphibians. In 
Figure 9 are collected only few examples which give idea of the widely different 
structures containing the piperidine unit. The highly structural diversity involves 




























FK 453  
Piperidine-containing compounds may be very simple, as in the case of (+)-
coniine (an alkaloid found in poison hemlock and responsible of its neurotoxic 
effect), or more complex, as the morphine (one of the most known piperidinyl 
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alkaloids and the most abundant of at least 50 alkaloids of several different types 
present in opium). Other example of piperidinyl alkaloids are Pumiliotoxin C, 
present in the poison of the Dendrobates auratus (a Central American species of 
frog), and Lobeline, extracted from Lobelia inflate and used as smoking 
cessation aid. Finally, piperidine nucleus can be found also in pharmacologically 
active man-made products such as FK453, an adenosine receptor antagonist 
with diuretic activity.  
The wide presence of piperidine-containing structures among natural and 
biologically active compounds justifies new efforts toward the development of 
valuable synthetic approaches for complex and differently functionalized 
products. 
 
Our contribution in this field was aimed to the achievement of new enantiopure 
heteropolycyclic piperidines having complex structures and/or particular 
functionalization groups by an approach of “diversity-oriented syntheses”, 
starting from a suitable building block. Diversity oriented synthesis (DOS) aims to 
synthesize a collection of compounds that differ substantially in their molecular 
structure.6 This has application in aspects of chemical genetics and drug 
discovery. 
The planning of the work was inspired by an article published on Journal of 
Organic Chemistry 2003,7 that reported the obtainment of pure enantiomers of 2-



















The configurational stability of 23 and the wide spectrum of reactivity of the 
corresponding aldehyde 24 make possible to employ one of the enantiomers 23a 
and 23b as starting material for the enantioselective synthesis of a number of 
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natural products. In Figure 10 are collected the results already obtained starting 





































 R'=R''=Me α-OH (-)-sedamine
 R'=H, R''=Et α-OH (+)-2'-ethylnorlobelol





In particular, we tried to widen this library exploiting the easy availability of 
enantiopure (R)- and (S)-2-allyl-piperidines 25, obtained by Wittig reaction on the 












THF, 0 °C     r.t.
24 25  
This goal was achieved gaining the compounds depicted in Figure 11. In fact, 
we envisioned some suitable synthetic procedures based on intramolecular 
transition metal-catalyzed reactions involving the allylic carbon-carbon double 
bond and suitable tethers linked on the position 1 of the piperidine ring. The 
functionalization of the nitrogen atom gave access to six- or seven-membered 
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ring fused systems by Pd(0), Pd(II) and Ru catalyzed reactions. Moreover, the 
intrinsic value and the molecular complexity of the first-cyclization products 
containing a further carbon-carbon double bond was increased by following 




























2.1.1. Synthetic sequence based on intramolecular H eck reaction 
 
Firstly we took into account the compound (R)-26, suitable for an intramolecular 
Heck reaction. Removal of the terbutoxycarbonyl group from (R)-25  with TFA 
and following treatment of a toluene solution of the deprotected piperidine with 
the commercially available 2-iodo-benzyl bromide in the presence of K2CO3 gave 


















































The Heck reaction was performed either in the presence of Pd(PPh3)4 as 
catalyst and TEA as base in acetonitrile or in ligand-free conditions10 in the 
presence of Pd(OAc)2 as catalyst, Na2CO3 and Bu4NCl in DMF. Both the 
procedure were effective to promote the formation of the benzo[e]pyrido[1,2-
a]azepine derivative (R)-27, even if the best result was obtained working with the 
former procedure (76% vs 38% yield). The related mechanism is depicted in 
Figure 12. The oxidative addition of the aryl iodide to the in situ generated Pd(0) 
species generates the aryl-Pd(II)-complex A. Coordination of the alkene moiety 
and subsequent carbon-carbon bond formation by syn addition provide the σ-
alkylpalladium(II) intermediate B, which readily undergoes β-hydride elimination 
to release the alkene Heck product (R)-27. The base is required for conversion of 
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The presence of the exomethylenic carbon-carbon double bond on the 
compound (R)-27, furnished the hint to reach more complex spiro-annulated 
structures by means of 1,3-dipolar cycloadditions. The dipolarophilic behaviour of 
the exocyclic carbon-carbon double bond was proven toward the 3,5-dichloro-
2,4,6-trimethylbenzonitriloxide (28), chosen as 1,3-dipole due to its excellent 
stability.11 
The reaction between (R)-27 and 28 was performed in toluene at reflux by 
using equimolar amounts of the reactants. As foreseeable by literature data,12 the 
cycloaddition took place with total regioselectivity giving, however, a mixture of 
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two diastereoisomeric products in approximately 3:1 ratio which were isolated by 
column chromatography in 68 and 19% yield, respectively. The 11-5’ junction of 
the benzo[e]pyrido[1,2-a]azepine-isoxazole system was inferred by the 1H and 
13C-NMR data, in particular by the geminal coupling constants greater than 17 
Hz, which is compatible only with the methylenic group for a 4-position of the 
isoxazole ring.13 It should be pointed out that a total regioselectivity was 
observed, accordingly to the literature data dealing with nitrile oxide 
cycloadditions to 1,1-disubstituted ethylenes. The distinction between the 
diastereoisomeric spiro-compounds 29 and 30 was established by X-ray 








2.1.2. Synthetic sequence based on intramolecular P d(II)-catalyzed 
chloroamination 
 
The Pd(II)-catalyzed functionalization of unactivated C-H bonds is actually a 
challenging field in organic chemistry,14 where we recently put our interest.15 
Recent literature seems particularly attracted by reactions achieving a double 
functionalization of double bonds, more specifically towards diamination or 
heteroamination processes.16,14n After an appropriate functionalization of the 
nitrogen atom, the ethylenic double bond present on compound (R)-25 seemed 
therefore suitable to perform such a goal. After deprotection with TFA, reaction 
with 4-nitro-phenylisocyanate afforded compound (R)-31, which bears a 
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nucleophilic nitrogen atom (Scheme 4). This latter easily reacts with the carbon-
carbon double bond using Pd(CH3CN)2Cl2 as catalyst and CuCl2 as oxidant; the 
high amount of copper chloride warrants the massive presence of chloride 
anions in the reaction medium, thus letting them intercept the σ-alkyl-palladium 
intermediate before a competitive β-hydride elimination process could occur. 
Consequently, bicyclic pyrido[1,2-c]pyrimidinone (3S,4aR)-32 is formed. This 
chlorinated product, whose stereochemistry has been undoubtedly assigned by a 

























CuCl2 (3 equiv.), 




Concerning the mechanism of the reaction, it is reasonable an initial 
coordination of palladium to the ethylenic double bond giving the π-olefin A, 
followed by nucleophilic attack of nitrogen atom on the internal carbon atom and 
formation of the σ-alkyl palladium complex B. The final step involves a reductive 
elimination of the metal giving the product 32. In this case, the expected 
elimination of the hydrogen in β-position is inhibited probably due to the excess 
of chloride ions.17 Finally, palladium will be ejected in the oxidation state zero and 

























































2.1.3. Synthetic sequence based on RCM reaction 
 
Application of ring closing metathesis to build large- and medium-ring 
heterocycles has enormously increased in recent years, due to the high 
efficiency this process usually warrants.18 Reasoning once more on substrate 
(R)-25, we thought to build a six-membered fused-ring on the piperidine by a 
RCM process performed on a substrate obtained by functionalization of the 
nitrogen with an acryloyl group. Reaction of the deprotected allyl piperidine with 
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acryloyl chloride furnished the appropriate substrate containing two ethylenic 
double bonds, which lie juxtaposed for the construction of a six-membered fused 
ring. Moreover, the presence of an amide group instead an amine one should 
have warrant easier the following RCM. In fact, amide (R)-33, treated with a 
Grubbs catalyst of 2nd generation 34 in DCM at reflux, conveniently furnished 












































Generally, the mechanism of ring closing metathesis consists in an initial 
coordination of an olefin to the metal alkylidene species A giving B, formation of 
the metallacyclobutane complex C and subsequent release of a different olefin, 
results in the formation of a new metal alkylidene D (Figure 15). This species can 
then undergo the same sequence of transformations involving the ethylenic 
double bond of the acryloyl group to give the final product (R)-35.  
As shown in Figure 15, reasonably first attack involves the allylic carbon-carbon 
double bond. In fact, olefin methatesis of electron-poor double bonds is less 
favoured compared to neutral olefins because the relative instability of electron-
deficient metal carbene bonds.19,20,21 In the case of RCM between α,β-
unsaturated carbonyl compounds and neutral terminal olefins it has been 
reported that the catalyst reacts preferentially with the neutral double bond, 
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before metathesizing the electron-poor olefin to form the cyclized product.20b On 
the other hand, after metathesis of the unhindered olefin, the carbonyl function in 
the resulting carbene complex (E) can chelate to the metal center thereby 




































Then, we decided once more to increase the molecular complexity of our 
product envisaging to employ the endocyclic double bond as dipolarophile in a 
1,3-dipolar cycloaddition with nitriloxide 28. As in the case of the 1,1-
disubstituted ethylenic compound (R)-27, the outcome of the cycloaddition on the 
1,2-disubstituted ethylenic double bond was totally regioselective, allowing the 
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formation of a 4,5-dihydroisoxazole product in 72% yield. Spectroscopic data 
agree with the structure (R)-36, having the carbonyl group in 4-position of the 
new formed isoxazoline. From the stereochemical point of view, the cycloaddition 
process allowed exclusively a cis-disposition of the two new stereocentres, which 
relative configuration was proven to be trans with respect to the pre-existing one 






2.2. Synthesis of tetracyclic benzodiazepines 
 
The second part of the thesis was inspired by the relevant role occupied in 
medicinal chemistry by 1,4-benzodiazepines.23 Among them, one of the most 
privileged class of these structures is held by 1,4-benzodiazepin-5-ones, a 
subset recognized as endowed with the anxiolytic, anticonvulsant, antiepileptic, 
muscle relaxant, antidepressant, sedative and hypnotic activities related to the 
treatment of CNS disorders.24 Moreover, this range of therapeutic activities has 
been strongly widened by annulations of the benzodiazepine skeleton to another 
carbo- or heterocyclic ring. Tricyclic 1,4-benzodiazepin-5-one systems, beyond 
solving anxiety and stress problems as in the case of flumazenil (37),25 count 
antihistaminic compounds such as tarpane (38),26 antibiotics like the pyrrolo-
fused abbeymicin27 (39) and antitumors having structure 40 (Figure 17).28 More 
recently, inspired by the attention given to bretazenil (41) due to its potential 
application towards neurodegenerative diseases,29 some tetracyclic 1,4-
benzodiazepinones have appeared in the literature. These structures have the 
benzodiazepine nucleus fused to different hetero- and carbocycles such as 














































Now, this work concerns a synthetic protocol for a new class of tetracyclic 1,4-
benzodiazepin-5-ones that we have been developed through our recent interest 
on allenylamides heterocyclization.31 The starting point for planning the new 
synthetic strategy is born from the recent achievement of the enantiopure 2-
vinylimidazolidinones 43, obtained by heteroannulation of the amino 
allenylamides 42 (Scheme 6).31 The reaction proceeds by a domino 
carbopalladation / 5-exo-allylic amination through the formation of the π-allyl-
complex A. The imidazolidinones 43 have been advised as building blocks for 
the construction of the 1,3-dipolar substrates suitable to intramolecular 
























































First of all, having recognized the major diastereoisomer imidazolidinones 
(2R,5S)-43 as the convenient starting materials, our approach required the 
synthesis of 2-aminobenzamides 47 as suitable compounds for accessing to the 
azide and nitrilimine 1,3-dipoles due to the presence of the aniline moiety. To this 
purpose, Boc-protection was removed by treatment with TFA to give 
imidazolidinones 44 (Scheme 7). These latter were functionalized by reaction 
with 2-nitrobenzoyl chloride (45) to give the 2-nitrobenzamides 46, which in turn 







































a: R = Me; b: R = i-Pr; c: R = Bn  
 
The diazotization of the aniline unity permitted the access to the corresponding 
azido compounds, but their intramolecular 1,3-dipolar cycloadditions furnished 
unstable 4,5-dihydro-1,2,3-triazole products which evolved into complex mixtures 
without synthetic interest. Such a failure prompted us to turn our attention to the 
nitrilimine 1,3-dipole, being a well established functional group in the synthesis of 
variously substituted azoles.32 To this end, compounds 47 were submitted to 
diazotization and following coupling with ethyl 2-chloroacetacetate to furnish the 
hydrazonyl chlorides 48, precursors of the transient nitrilimine species 49. In fact, 
the treatment of 48 with triethylamine in boiling toluene gave directly the 
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a: R = Me; b: R = i-Pr; c: R = Bn  
 
Further to the total regiochemical outcome, that was expected as a 
consequence of the propargylic nature of the 1,3-dipole, the cycloaddition 
reaction was totally diastereoselective giving rise to only one diastereoisomer 
product. This feature, highly important from the synthetic point of view, probably 
arises from the bulky phenyl substituent and the rather rigid imidazolidinone 
moiety working against the intramolecular approach of the dipole to the si face of 
the dipolarophile, so dictating the exclusive formation of the cis diastereoisomer 
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50. The absolute configuration was assigned by 1H-NMR NOESY experiments 
carried out on compound 50a. As shown in Figure 18, further to obvious 
interactions between the hydrogens in 2- and 5-positions of the imidazole 
nucleus, the cross-peak between the hydrogen in position 2 of the 
imidazolidinone and those in orto to the phenyl group resulted determinant to 
identify the S-configuration of the newly created stereocentre, determining the 
formation of the (3aS,3bR,6S)-diastereoisomer. The enantiomeric purity was 
proven to be better than 99.5% by HPLC analysis with AD chiral column of 
compound 50a, performed in comparison to a sample of the corresponding 
racemic mixture synthesized starting from the (±)-alanine. 
 
 
















Selected NOESY correlations for compound 50a. 
 
 
We next examined the procedure by using imidazolidinones 43 and 5-chloro- 
and 5-fluoro-2-nitro-benzoyl chlorides in order to improve the scope of the 
reaction and the interest of the products from the biological point of view, having 
a halo-substituted 1,4-benzodiazepine nucleus. In Table 1 are collected the 
halide-containing 2-nitrobenzamides 46, 2-aminobenzamides 47, hydrazonyl 
chlorides 48, and tetracyclic products 50. The preparations of hydrazonyl 
chlorides as well as the nitrilimine cycloadditions occurred analogously to the 













    
    
    
    
    











































































































































































































































































2.3. Pd(II)/Cu(II) catalyzed intramolecular aminoca rboxylation of 
aminoalkenes for the synthesis of bicyclic oxazolid inones 
 
The third section of the thesis was focused on a divergent synthesis of 
piperazinones and bicyclic oxazolidinones starting from allyl amides of α-amino 
acids. 
Piperazines and piperazinones have relevant biological and pharmacological 
interest, often present in the core-structures of compounds with antifungal,33 
antidepressant,34 antimigraine,35 antithrombotic,36 antihystaminic,37 and 
nootropic38 activities. Moreover, bicyclic oxazolidinones constitute a fruitful 
source of hydroxylated nitrogen-containing ring systems.39  
The hint for these studies arose by our interest on the Pd(II)-catalyzed 
intramolecular reactions of nucleophiles, such as amides or electron-rich 
heteroaromatic compounds, onto multiple carbon-carbon bonds.15a-c More 
specifically, during our investigations on amination reactions in oxidative 
conditions, we envisaged the cyclization of allyl amides of α-amino acids as route 
to access piperazinone derivatives. 
Preliminary studies were performed on Boc-glycine-N-allyl-N-cyclohexyl amide 
51 to examine the activity of different catalysts and oxidants, and revealed a 
remarkable role of CuCl2. In fact, the divergent formation of cyclization products 
52 and 53 was observed, depending solely on the amount of CuCl2, either 
catalytic or stoichiometric (Scheme 9). In particular, compound 2 was obtained 
using PdCl2(MeCN)2 (5 mol%) and CuCl2 (10 mol%)/O2 as the oxidant system in 


































Albeit the amination reaction giving dihydropirazinone 52 undoubtedly 
constitutes an unprecedented result in aza-Wacker type reactions, the alternative 
formation of the bicyclic oxazolidin-2-one 53 by exposure of 51 to a 
stoichiometric amount of CuCl2 (Scheme 9, path b) represents a much more 
striking breakthrough. So, we devoted our efforts to improve the latter domino 
procedure, which would furnish hydroxymethyl-substituted piperazinone after 
oxazolidinone ring-opening. The interst for this result is increased because 
• product 53 is generated by an unusual behavior of the carbamate 
oxygen which acts as a nucleophile in an oxidative Pd(II)-catalyzed 
reaction involving a domino aminocarboxylative process based on an 
initial carbon-nitrogen bond formation, followed by an intramolecular 
carboxylation reaction, involving the terbutoxycarbonyl group. 
• several procedures for the formation of oxazolidinones featuring a Pd-
catalyzed cyclization of O-allyl carbamates have been reported, but 
these normally involve the C-N bond formation.40 However, to the best 
of our knowledge, only a single example of carbamate cyclization via 
C-O bond formation has been described, which does not claim for a 
palladium intermediate.41 
The reaction conditions were then investigated to optimize the formation of the 
synthetically valuable fused-oxazolidin-2-one bicyclic products 53.42 An excess of 
CuCl2 yielded 53 in higher amount (Table 1, entry 2 vs 1). Both palladium and 
cupric chloride were required, since the conversion of 51 was precluded by 
removal of PdCl2(MeCN)2 as well as by the use of other oxidants such as 
Cu(OAc)2, 1,4-benzoquinone, or PhI(OAc)2 (entries 3-6). 
Similar yields were obtained running the reaction in an open vessel or under 
nitrogen atmosphere. The reaction occurred also at room temperature, but the 
yield of 53 is noticeably lower (entry 7). Further screening of different solvents 
proved to be unfruitful to improve the yields or to gain milder conditions (entries 
8-10). Changing the source of palladium, namely with Pd(OAc)2, no conversion 
took place (entries 11, 12). It is worth mentioning that the formation of the 
intramolecular amination product 52 was never observed using CuCl2 in 























Entry Catalyst Oxidant (eq). Solvent T (°C) Yield ( %)a 
1 PdCl2(MeCN)2 CuCl2 (1) DMF 100 69 
2 PdCl2(MeCN)2 CuCl2 (3) DMF 100 81 
3 - CuCl2 (3) DMF 100 n.r. 
4 PdCl2(MeCN)2 Cu(OAc)2 (3) DMF 100 n.r. 
5 PdCl2(MeCN)2 1,4-BQ (2) DMF 100 n.r. 
6 PdCl2(MeCN)2 PhI(OAc)2 (3) DMF 100 Traces 
7 PdCl2(MeCN)2 CuCl2 (3) DMF r.t. 64 
8 PdCl2(MeCN)2 CuCl2 (3) THF Reflux 40 
9 PdCl2(MeCN)2 CuCl2 (3) CH2Cl2 Reflux 26 
10 PdCl2(MeCN)2 CuCl2 (3) Toluene 80 n.r. 
11 Pd(OAc)2 Cu(OAc)2 (3) DMF 100 n.r. 
12 Pd(OAc)2 1,4-BQ (2) DMF 100 n.r. 




The domino reaction is not dependent on the carbamate protecting-group 
(Scheme 10), as it operated also on Cbz-, Fmoc- and ethoxycarbonyl-glycine 
amides 54 providing the oxazolidin-2-one 53, although in lower yields (48%, 23% 
















a: PG = Cbz, 48%
b: PG = Fmoc, 23%
c: PG = CO2Et, 40%





The scope of this transformation was then explored, reacting the easily 






















5755 a-h  
Boc PdCl2(MeCN)2 , CuCl2 
DMF; 24 h, 100 °C
 
 
Table: 3  
 
Entry R R’ Dr ratio Isolated yields(%) 
1 i-Pr Cyclohexyl 70:30 56a (56%) 57a (23%) 
2 i-Pr Cyclopentyl 75:25 56b (48%) 57b (18%) 
3 i-Bu Cyclohexyl 80:20 56c (62%) 57c (15%) 
4 i-Bu Cyclopentyl 80:20 56d (62%) 57d (9%) 
5 Bn Cyclohexyl 75:25 56e (41%) 57e  (13%) 
6 Bn Cyclopentyl 70:30 56f (57%) 57f (25%) 
7 Me Cyclohexyl 80:20 56g (55%)  
8 Me Cyclopentyl 80:20 56h (49%)  
      
 
 
In all these cases, the reactions provided the desired oxazolo[3,4-a]pyrazine 
derivatives as a mixture of two diastereoisomers. The relative configurations of 
the major and minor products, namely trans and cis, were identified by single-
crystal X-ray analysis, performed on isopropyl-substituted compounds 56b and 






























The amination products (Scheme 9, path a) were never isolated nor detected in 
the NMR spectra of the crude reaction mixtures. On the other hand, the 
dihydropyrazinone derivatives 58 resulted the sole products, when a number of 





















DMF, 100 °C, O 2
BocBoc
 
Entry R R’ Yield 
1 i-Pr Cy 58a (82%) 
2 i-Pr Me 58b (55%) 
3 i-Bu Cy 58c (82%) 
4 i-Bu Me 58d (72%) 
5 Bn Cy 58e (71%) 
6 Bn Me 58f (65%) 
7 Me Cy 58g (83%) 
8 Me Me 58h (70%) 
    
 
 
The domino process is not limited to the allylamides of α-amino acids, but can 
be extended to other carbamate-protected aminoalkenes having a more flexible 
tether. In fact, the Boc-amino allylethers 59a and 59b, synthesized gave the 
bicyclic morpholino derivatives 60a and 60b in good yields (Scheme 12). 
 
















60a, R = H, 75% yield
60b, R = Me, 82% yield  
 
 
Boc-amino allylethers 59a and 59b were prepared from the corresponding 1,2-
amino alcohol (Scheme 13). The introduction of allyl group on protected Boc-
61a,b43,44 derivative was more laborious than expected. The allylation was done 
through palladium catalyst-allylation process using Pd(PPh3)4 (2 mol%) in THF 
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and allyl methyl carbonate.45 In Scheme 13 is shown the mechanism of the 
outcome of the reaction. The species of Pd (0) coordinates to the double bond 
resulting in π-allyl complex, with removal of the carbonate group. Hydroxyl 
functionality at this point acts as a nucleophile, forming the allylether and 























59a (R = H, 50%)
59b (R = Me, 60%)






While glycinol is commercially available, its dimethyl-substituted analogue 6246 
was prepared by reduction of the corresponding amino acid. The nitrogen 



































Further, we investigated the feasibility of the reaction to N-allyl-N'-Boc 
ethylendiamine in order to access the oxazolidinones on fused piperazine ring.  
As the most suitable approach to access the desired compound 68 we envisaged 
the sequence depicted in Scheme 15. Firstly, the N-tosyl glycinol (63)47 was 
 36
converted into the silyl derivative (64)48 and subsequently treated with allyl 
bromide, sodium hydride as base, in a mixture of THF / DMF as solvent to give 
the product 65 in 75% yield. The protecting group was removed to form the 
alcohol 66,49 whose hydroxyl functionality was converted into an azide group via 
a Mitsunobu reaction yielding the derivative 67. The formation of the Boc-












































The compound 68 was subjected to cyclization reaction under the 
aminocarboxylation conditions fruitfully used in case of derivatives 51, 55 and 59. 
The reaction led to the formation of a single product, which is a fused-bicycle ring 
structure that contains oxazolidinones and piperazine units. The product 69 was 




















Although the mechanism leading to the dihydropyrazinone derivative 52 
plausibly proceeds following a typical amination path, the aminocarboxylative 
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products arise from a more complex and unusual domino process, still 
uncleared. 
The amination process, shown in Scheme 17 for compound 51, arose by initial 
coordination of the Pd(II) salt to the carbon-carbon double bond to give the π-
olefin complex A, followed by the nucleophilic attack of the nitrogen atom with 
generation of the σ-alkyl-palladium complex B. Finally, β-hydride elimination 
produces the exo-methylene derivative C, neither isolated nor detected in the 




































































Product 53 is obtained via a domino aminocarboxylative process based on an 
initial carbon-nitrogen bond formation, followed by an intramolecular 
carboxylation reaction, involving the terbutoxycarbonyl group. This is an unusual 
behavior of the carbamate oxygen which acts as a nucleophile in an oxidative 
Pd(II)-catalyzed reaction.  
To have a better insight onto this domino aminocarboxylative process, two 
more reactions were studied. In a first instance, allylamide 51 was reacted using 
CuCl2 (10 mol%)/O2 as oxidant in the presence of excess LiCl (5 equiv), leading 























 Subsequently, the cyclization of the acetyl glycine amide 70, lacking the 
carbamate group, was investigated in the aminocarboxylative conditions. Also in 
this case, the reaction underwent only the β-hydride elimination process affording 
71 (Scheme 19). In both reactions, a putatively stable chloro derivative, resulting 
from a nucleophilic substitution of the Pd(II) moiety by a chloride anion, was 


























A possible rationalization of the aminocarboxylative reaction consists in an 
oxidative CuCl2-assisted Pd-elimination from the σ-alkylpalladium complex A, 
arising from the initial aminopalladation (Scheme 20). In this case, the PdCl 
moiety behaves as a leaving group in the intramolecular nucleophilic attack of 
the carbamate oxygen, which generates the species B. CuCl2 would inhibit the 
more straightforward palladium β-hydride elimination through a transient 
palladium oxidation (path a)50 or by formation of a heterobimetallic σ-Pd/Cu 
complex (path b).51 Finally, B can evolve to the product 53 through the 
intervention of a nucleophile such as the chloride anion or water present in the 
reaction medium. However, further studies on mechanistic evaluations of this 


















































































In summary, during the course of this Ph.D. thesis several goals concerning the 
access to fused-ring heterocycles were achieved. All the molecular targets were 
obtained in enantiopure form making use of reactions on ethylenic double bonds, 
very often in the presence of transition metal catalysts. 
 
Firstly, the availability of the 2-allyl-piperidine synthon in enantiopure form 
allowed performing new synthetic methodologies which involve the olefin double 
bond in intramolecular reactions to increase the molecular complexity of 
piperidine-containing structures, suitable for further transformation. The different 
synthetic routes, in addition to the several ones already reported in the literature, 
make 2-allyl-piperidine as a valuable synthon for the Diversity Oriented 
Synthesis.  
  
Secondly, we have reported the procedure for the synthesis of a new class of 
tetracyclic 1,4-benzodiazepin-5-ones, having an imidazo[2,1-c]pyrazolo[1,5-
a][1,4]benzodiazepin-5,8-dione structure. The key steps upon which relies the 
synthetic protocol consist of i) a palladium-catalyzed heteroannulation of 
allenylamides, easily accessible from α-aminoacids, that gives rise to imidazole 
ring and ii) an intramolecular nitrilimine cycloaddition, providing the simultaneous 
formation of the 1,4-diazepine and pyrazole rings. Moreover, the novel scaffold of 
heteropolycyclic systems was accessible in enantiopure form, inferred by the 
starting α-aminoacids and well kept during the synthetic sequence. 
 
Finally, we have discovered a divergent oxidative Pd(II)-catalyzed cyclization of 
carbamate protected aminoalkenes, strictly dependent on the amount of CuCl2 
(catalytic vs stoichiometric). The domino aminocarboxylative cyclization leads to 
bicyclic oxazolidinones via a C-O bond-forming reductive carboxylation triggered 
by stoichiometric CuCl2, after an initial aminopalladation step. This is, to the best 
of our knowledge, the first example of oxidative Pd(II)-catalyzed reactions 























Melting points were determined by the capillary method with a Büchi B-540 
apparatus. Optical rotations were measured with a Jasco P-1010 polarimeter at 
25°C . 1H NMR and 13C NMR spectra were recorded with an AVANCE 400 
Bruker spectrometer. The chemical shifts are given in ppm and the coupling 
constant in Hz.   
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To a solution of Dess Martin 97% (1.35 g, 3.10 mmol) in dry CH2Cl2 (23 mL) 23 
(0.64 g, 2.82 mmol) was added. The reaction mixture was left at room 
temperature under agitation for 3 hours. Then Et2O (29 mL) and NaOH 1 mol/L 
(29 mL) were added. The reaction mixture was left under agitation for other 10 
minutes. The organic phase was washed by NaOH 1 mol/L (29 mL) and then by 
water (40 mL), the organic phase was dried with Na2SO4 and the solvent is 
evaporated at reduced pressure. We obtained colorless oil with 90 % yield. 
 












To a suspension of Ph3P
+CH3I
- (2.06 g, 5.09 mmol) in dry THF (25 mL) under 
nitrogen atmosphere at 0 °C t-BuOK (0.57 g, 5.09 mmol) was added. The 
mixture was left at 0°C for 10 minutes. 24 (0.50 g, 2.21 mmoli) dissolved in dry 
THF (8 mL) was added drop by drop, the reaction mixture was left under 
agitation at room temperature for 20 hours. THF was evaporated and water (15 
mL) was added. Then it was extracted by AcOEt (30/25/20 mL) the organic 
phase was dried with Na2SO4 and then evaportated. The crude 25 was purified 
by column chromatography (hexane/AcOEt 24:1). 
Yeld = 72% 
Colorless oil 
[α]D25 = +49.5    (c = 0.910 g/L, CHCl3) 
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dry toluene, 70 °C
0 °C r.t.
25 26  
 
To compound 25 (0.355 g, 1.58 mmol) trifluoroacetic acid (1.8 mL, 23.65 mmol) 
was added drop by drop under nitrogen atmosphere at 0 °C. The reaction 
mixture was left under vigorous stirring for 3 h at room temperature. 
Trifluoroacetic acid was evaporated. The residue was dissolved in anhydrous 
toluene (4 mL) and was added drop by drop to a suspension of K2CO3 (6.45 g, 
46.7 mmol) and 2-iodo-benzilbromuro (468 mg, 1.58 mmol) in anhydrous toluene 
(12 mL) at 40 °C. Then the reaction mixture was hea ted to 70 °C for one night. 
Ice-cold water (22 mL) was added to the reaction mixture and then was extracted 
by Et2O (2 x 17 mL). The organic phase was dried over Na2SO4 filtered and 
concentrated under vacuum. The crude 26 was purified by silica gel column 
chromatography (EdP/AcOEt 98:2). 
Yield:  94%  
Yellow oil 
[αd]D25 = +31.1    (c = 1.093g/L, CHCl3) 
1H-NMR (CDCl3)  δ 1.32-1.61 (4H, m), 1.63-1.78 (2H, m), 2.17-2.28 
(1H, m), 2.30-2.45 (2H, m), 2.50-2.62 (1H, m), 
2.68-2.76 (1H, m), 3.39, 3.91 (2H, AB system, J = 
14.8 Hz), 5.03 (1H, d, J = 9.6 Hz), 5.05 (1H, d, J 
= 17.6 Hz), 5.84 (1H, ddt, J = 9.6, 17.6, 7.1 Hz), 
6.94 (1H, dd, J = 7.3, 7.8 Hz), 7.33 (1H, dd, J = 
7.3, 7.5 Hz), 7.54 (1H, d, J = 7.5 Hz), 7.81 (1H, d, 
J = 7.8 Hz) 
 
13C-NMR (CDCl3)       δ 23.3 (t), 26.1 (t), 30.6 (t), 35.9 (t), 51.7 (t),60.8 (d), 
62.9 (t), 100.6 (s), 116.8 (t) 128.5 (d), 128.8 (d), 
130.5 (d), 136.7(d), 139.6 (d), 142.6 (s) 
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Synthesis of ( R)-11-Methylene-1,2,3,4,6,11,12,12a-octahydro-







26 27  
 
To a solution 26 (0.32 g, 0.931mmol) in anhydrous acetonitrile (10mL) 
Pd(PPh3)4 99% (0.12 g, 0.0931 mmol) and triethylamine (389 mL, 2.79 mmol) 
were added. The reaction mixture was heated under reflux for 2 h, the solvent 
was evaporated under reduced pressure. Water (10 mL) was added to the 
residue and it was extracted by CH2Cl2 (2 x 16 mL). The organic phase was dried 
over Na2SO4 filtered and concentrated under vacuum. The crude 27 was purified 
by silica gel column chromatography (EdP/AcOEt 5:1).  
Yield: 68%  
Dark yellow oil 
[αd]D25 = -41.8    (c = 0.250g/L, CHCl3) 
 
1H-NMR (CDCl3) δ 1.32-1.40 (1H, m), 1.54-1.77 (5H, m), 2.35-2.47 
(2H, m), 2.48-2.62 (2H, m), 2.88-2.96 (1H, m), 
3.74, 3.80 (2H, AB system, J = 14.9 Hz), 5.09 (1H, 
s), 5.25 (1H, s), 7.10 (1H, d, J = 8.4 Hz), 7.16-7.26 
(2H, m), 7.34 (1H, d, J = 8.4 Hz) 
 
13C-NMR (CDCl3) δ 24.0 (t), 26.3 (t), 30.1 (t), 32.8 (t), 42.0 (t), 55.8 (t), 
62.2 (t), 64.5 (d), 114.2 (t), 127.7 (d), 127.8 (d), 






























To a solution 27 (61.0 mg, 0.286 mmol) in dry toluene (1.5 mL) 28 (65.8 mg, 
0.286 mmol) was added. The reaction mixture was heated under reflux for 12 h; 
the solvent was evaporated under reduced pressure. The crude was purified by 




spiro{benzo[ e]pyrido[1,2- a]azepine-11,5’-isoxazole} (29).  
Yield:  42% 
White crystal 
M.p. 185 - 186°C  
[αd]D25 = +33.3    (c = 0.271g/L, CHCl3) 
1H-NMR (CDCl3) δ 1.15-1.25 (2H, m), 1.38-1.52 (1H, m), 1.58-1.74  
(3H, m), 2.13-2.35 (2H, m), 2.19 (3H, s), 2.24 (3H, 
s), 2.38-2.49 (2H, m), 2.53 (3H, s), 2.80-2.89 (1H, 
m), 3.29, 3.39 (2H, AB system , J = 17.5 Hz), 3.62, 
4.29 (2H, AB system, J = 14.8 Hz), 7.14 (1H, d, J = 
7.4 Hz), 7.25 -7.43 (2H, m), 7.63 (1H, d, J = 7.4 
Hz).  
       
13C-NMR (CDCl3)    δ 18.5 (q), 19.4 (q), 24.7 (t), 26.6 (t), 33.5 (t), 48.0 (t), 
54.4 (t), 55.2 (t), 59.1 (d), 59.4 (t), 90.8 (s), 125.9 
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(d), 128.5 (d), 129.2 (s), 130.3 (s), 130.9 (d), 133.7 





spiro{benzo[ e]pyrido[1,2- a]azepine-11,5’-isoxazole} (30).  
Yield:  29% 
Brown oil 
[αd]D25 = -37.7(C = 0.105g/L, CHCl3)  
1H-NMR (CDCl3)  δ 1.23-1.72 (7H, m), 1.74-1.83 (1H, m), 2.02-2.09 
(1H, m), 2.15 (6H, s), 2.42-2.51 (1H, m), 2.52 (3H, 
s), 2.78-2.87 (1H, m), 3.02, 3.61 (2H, AB system, 
J = 17.1 Hz), 3.63, 3.76 (2H, AB system, J = 14.5 
Hz), 7.20 (1H, d, J = 7.7 Hz), 7.22-7.36 (2H, m), 
7.73 (1H, d, J = 7.7 Hz) 
      
13C-NMR (CDCl3)           δ 18.4 (q), 19.4 (q), 22.9 (t), 26.1 (t), 30.1 (t), 34.1 
(t), 43.8 (t), 49.4 (t), 62.1 (d), 63.8 (t), 90.3 (s), 
125.2 (d), 128.3 (d), 129.3 (s), 131.9 (d), 133.6 (s), 








































25 31  
 
 
To compound 25 (0.355 g, 2.58 mmol) trifluoroacetic acid (1.8 mL, 23.65 mmol) 
was added drop by drop under nitrogen atmosphere at 0°C. The reaction mixture 
was left under vigorous stirring for 3 h at room temperature. Trifluoroacetic acid 
was evaporated. The residue was dissolved in anhydrous THF (4 mL) and 4-
nitrophenyl isocyanate (423 mg, 2.58 mmol) was added. Then the reaction 
mixture was left under agitation at room temperature all night. The solvent was 
evaporated, brine (22 mL) was added to the resedue and then the mixture was 
extracted by CH2Cl2 (2 x 17 mL). The organic phase was dried over Na2SO4 
filtered and concentrated under vacuum. The crude 31 was purified by silica gel 
column chromatography (EdP/AcOEt 7:3) 
Yield: 72% 
Yellow oil 
1H-NMR (CDCl3) δ 1.62-1.69 (6H, m), 2.27-2.33 (1H, m), 2.49-2.55 
(1H, m), 3.96 (1H,d, J = 16 Hz), 4.31 (1H, s, br), 
5.10 (2H, dd, J = 18.8, 28 Hz), 5.77 (1H, q), 7.12 
(1H, s, br), 7.51 (2H, d, J = 9.2Hz), 8.11 (2H, d, J = 
2.7 Hz) 
 
13C-NMR (CDCl3) δ 18.6 (t), 25.5 (t), 28.1 (t), 34.4 (t), 39.6 (t), 51.5 (d), 
117.8 (t), 118.4 (d), 124.9 (d), 134.9 (d), 142.1 (s), 
146.1 (s), 154.1 (s) 
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31 32  
 
CuCl2 98 % (0.13 g, 1 mmol.) and Pd(CH3CN)2Cl2 99 % (0.01 g, 0.05 mmol.) 
were dissolved in dry  DMF (10 mL). 31 (0.3 g, 1 mmol.) dissolved in dry DMF 
(10 mL) was added, the reaction mixture was left under agitation at 100°C for 2 h 
and 30 min. Brine was added to the reaction mixture and it was extracted 3 times 
with CH2Cl2.  The organic phase was dried with Na2SO4 and the solvent is 
evaporated at reduced pressure. The obtained crude was purified by a column 






25: -7.6 (c = 0.37 g/L, CHCl3) 
1H-NMR (CDCl3) δ 1.52-1.79 (7H, m), 2.53 (1H, m), 2.64 (1H, t), 3.44 
(1H, m), 3.59 (1H, t), 3.7 (1H, dd, J = 4.2, 4.3 Hz), 
4.09 (1H, m), 4.61 (1H, d, J = 14.6 Hz), 7.44 (2H, 
d, J = 15.2Hz), 8.20 (2H, d, J = 15.2 Hz) 
 
13C-NMR (CDCl3) δ 23.7 (t), 25.1 (t), 31.1 (t), 33.6 (t), 42.6 (t), 43.7 (t), 
50.8 (d), 57.3 (d), 124.4 (d), 125.4 (d), 144.4 (s), 



















25 33  
To the compound 25 (0.31 g, 1.39 mmol) triflouro acetic acid (1.6 mL, 20.83 
mmol) was added at 0 °C under nitrogen. The reactio n mixture was left at room 
temperature for 3 hours. The acid was evaporated. The amine was dissolved in 
dry CH2Cl2 (3 mL) and the triethylamine (581 µL, 4.17 mmol) and acryloyl 
chloride (0.15 g, 1.67 mmol.) were added. The reaction mixture was left at room 
temperature for one night. Water (3 mL) was added. And the mixture was 
extracted by CH2Cl2 (5 mL). The organic phase was dried by Na2SO4 and 




[α d ]D 25= +66.5    (c = 0.632 g/L, CHCl3) 
1H-NMR (CDCl3, 50°C)  δ 1.38-1.52 (1H, m), 1.60-1.74 (5H, m), 2.27-
2.40 (1H, m), 2.44-2.53 (1H, m), 2.93 (1H, s br), 
4.20 (1H, s br), 4.52 (1H, s br), 5.03-5.14 (2H, m), 
5.61 (1H, d, J = 10.7 Hz), 5.69-5.80 (1H, m), 6.19 
(1H, d, J = 16.9 Hz), 6.56 (1H, dd, J = 10.7, 16.9 
Hz)  
 
13C-NMR (CDCl3, 50 °C) δ 19.3 (t), 26.0 (t), 29.9 (t), 35.0 (t), 39.6 (t),50.8 (d), 
























To a solution 33 (67.40 mg, 0.376 mmol) in dry CH2Cl2 (7 mL) Grubbs of 
second-generation (16.00 mg, 0.019 mmol) was added. The reaction mixture 
was heated under reflux for 2 hours, and then the solvent was evaporated. 
Brown oil was obtained and it was purified by column chromatography 
(EdP/AcOEt 3:1). 
Yield:  98% 
Yellow oil  
[αd]D25= -254.4    (c = 0.533 g/L, CHCl3) 
1H-NMR (CDCl3) δ 1.37-1.49 (3H, m), 1.65-1.78 (2H, m), 1.80-1.86 
(1H, m), 2.12-2.23 (1H, m), 2.44-2.55 (2H, m), 
3.30-3.46 (1H, m), 4.48 (1H, d, J = 12 Hz), 5.85 
(1H, d, J = 9.8 Hz), 6.41-6.48 (1H, m),  
 
13C-NMR (CDCl3) δ 24.3 (t), 25.2 (t), 31.4 (t), 33.7 (t), 43.3 (t), 55.1 (d), 


































To a solution 35 (56.8 mg, 0.376 mmol) in dry toluene (2.0 mL) 28 (86.5 mg, 
0.376 mmol) was added. The reaction mixture was left under reflux for 18 hours, 
and then the solvent was evaporated. Brown oil was obtained and it was purified 
by column chromatography. (EdP/AcOEt 6:4) 
Yield:  68% 
Beige oil. 
[α d ]D25 = −83.0   (c = 0.912 g/L, CHCl3) 
1H-NMR (CDCl3) δ 1.26-1.37 (1H, m), 1.41-1.50 (2H, m), 1.74-1.81 
(1H, m), 1.83-2.00 (3H, m), 2.14 (3H, s), 2.33 (3H, 
s), 2.34-2.37 (1H, m), 2.38-2.42 (1H, m), 2.52 (3H, 
s), 3.60-3.68 (1H, m), 4.16 (1H, d, J = 10.2 Hz), 
4.43-4.50 (1H, m), 5.06-5.13 (1H, m) 
 
13C-NMR (CDCl3) δ 18.9 (q), 19.4 (q), 23.3 (t), 25.0 (t), 33.2 (t), 33.3 (t), 
42.8 (t), 50.5 (d), 57.6 (d), 77.4 (d), 128.4 (s), 133.1 






















43 a-c 44 a-c
  a R = Me, b R = i-Pr, c R = Bn  
A solution of (2R,5S)-4352 (2.55 mmol) in TFA (6 mL) was stirred at room 
temperature for 3 hours, then the solvent was evaporated under reduced 









































Pale yellow oil 
[α d]D
25: +27.5  (c = 0.37 g/L, CHCl3) 
IR: 1670 cm-1, 3430 cm-1 
1H-NMR (CDCl3) δ 1.38 (3H, d, J = 7.1 Hz), 3.04 (3H, s), 4.08 (1H, q, J 
= 7.1 Hz), 5.71 (1H, s), 5.72 (1H, s), 5.89 (1H, s), 
6.57 (1H, br s), 7.28 - 7.30 (2H, m), 7.42 - 7.48 (3H, 
m) 
 
13C-NMR (CDCl3) δ 14.7 (q), 28.1(q), 54.1 (d), 74.2 (d), 122.9 (t), 
































M.p: 93° C  
[α d]D
25: +22.5  (c = 0.45 g/L, CHCl3) 
IR: 1664 cm-1, 3428 cm-1 
1H-NMR (CDCl3) δ 0.87 (3H, d, J = 7.0 Hz), 1.00 (3H, d, J = 7.1 Hz), 
2.39 (1H, dqq, J = 3.9, 7.0, 7.1 Hz), 3.05 (3H, s), 
4.19 (1H, d, J = 3.9 Hz), 5.74 (1H, s), 5.87 (1H, s), 
5.98 (1H, s), 7.28 - 7.32 (2H, m), 7.41 - 7.50 (3H, 
m), 11.07 (1H, br s) 
 
13C-NMR (CDCl3) δ 16.4 (q), 18.2 (q), 28.1 (d), 28.9 (q), 60.1 (d), 74.6 
(d), 124.7 (t), 127.5 (d), 129.9 (d), 130.7 (d), 133.6 







































M.p. 91 °C 
[α d]D
25: -30.3 (c = 0.27 g/L, CHCl3) 
IR: 1682 cm-1, 3444 cm-1 
1H-NMR (CDCl3) δ 2.86 (3H, s), 3.13 - 3.20 (2H, m), 4.14 - 4.18 (1H, 
m), 5.14 (1H, s), 5.38 (1H, s), 5.54 (1H, s), 5.75 
(1H,br s), 7.08 - 7.36 (10H, m), 11.2 (1H, br s) 
 
13C-NMR (CDCl3) δ 28.8 (d), 34,3 (t), 59.3 (q), 74.9 (d), 124.1 (t), 127.3 
(d), 129.2 (d), 129.8 (d), 129.9 (d), 130.2 (d), 130.4 



































  a R = Me, b R = i-Pr, c R = Bn  
 
To a solution of 44 (0.7 mmol) in dry CH2Cl2 (3 mL) TEA (0.51 mL, 3.64 mmol) 
was added. The mixture was cooled at 0 °C and a sol ution of 45 in dry CH2Cl2 (2 
mL) was dropped under stirring. After 24 hours at room temperature the mixture 
was washed with 5% HCl (30 mL) and with aq. NaHCO3 (30 mL) then the organic 
layer was dried over Na2SO4. The solvent was evaporated and the crude mixture 














Pale yellow crystals 
M.p: 160° C 
 [α d]D
25: -10.20 (c = 0.10 g/L, CHCl3) 
IR: 1652 cm-1, 1704 cm-1.  
 (mixture of two conformers in ratio 2:1)  
 
Major conformer 
1H-NMR (CDCl3) δ 0.41 (3H, d, J = 6.9 Hz), 3.04 (3H, s), 3.78 (1H, q, J 
= 6.9 Hz), 5.56 (1H, s), 5.77 (1H, s), 6.06 (1H, s), 
6.98 - 8.26 (9H, m) 
 
13C-NMR (CDCl3) δ 18.2 (q), 27.5 (q), 55.6 (d), 79.2 (d), 122.3 (t), 124.9 
(d), 128.0 (d), 128.8 (d), 129.0 (d) 129.4 (d), 131.0 
(d), 132.0 (s), 134.8 (d), 138.1 (s), 144.4 (s), 144.8 
(s), 167.5 (s), 170.2 (s). 
 
Minor conformer 
1H-NMR (CDCl3)   δ 1.22 (3H, d, J = 6.9 Hz), 2.84 (3H, s), 4.65 (1H, q, J 
= 6.9 Hz), 4.69 (1H, s), 5.13 (1H, s), 5.31 (1H, s), 
6.98 - 8.26 (9H, m) 
 
13C-NMR (CDCl3) δ 16.9 (q), 27.4 (q), 55.8 (d), 80.1 (d), 122.4 (t), 125.2 
(d), 128.0 (d), 128.9 (d), 129.2 (d), 129.7 (d), 130.5 
(d), 132.2 (s), 134.8 (d), 136.8 (s), 144.4 (s), 144.9 
















Pale yellow crystals  
M.p.: 62° C 
 [α d]D
25: -13.50  (c = 26.7 g/L, CHCl3) 
IR: 1640 cm-1, 1690 cm-1 
 (mixture of two conformers in ratio 2:1) 
 
Major conformer 
1H-NMR (CDCl3)  δ 0.40 (3H, d, J = 6.8 Hz), 2.97 (3H, s), 3.74 (1H, q, J 
= 6.8 Hz), 5.50 (1H, s), 5.70 (1H, s), 5.98 (1H, s) , 
6.97 - 8.12 (8H, m) 
 
13C-NMR (CDCl3) δ 17.8 (q), 27.1 (q), 55.0 (d), 78.6 (d), 121.8 (t), 126.0 
(d), 126.4 (d), 127.3 (d), 128.4 (d) 128.7 (d), 130.6 
(d), 133.0 (s), 137.5 (s), 141.1 (s), 142.8 (s), 143.8 
(s), 165.3 (s), 169.4 (s). 
 
Minor conformer 
1H-NMR (CDCl3) δ 1.21 (3H, d, J = 6.5 Hz), 2.81 (3H, s), 4.57 (1H, q, J 
= 6.5 Hz), 4.75 (1H, s), 5.20 (1H, s), 5.32 (1H, s), 
6.98 - 8.12 (8H, m) 
 
13C-NMR (CDCl3) δ 16.4 (q), 26.9 (q), 55.3 (d), 79.4 (d), 122.1 (t), 126.0 
(d), 126.4 (d), 127.3 (d), 128.5 (d), 128.9 (d), 130.6 
(d), 133.1 (s), 136.2 (s), 141.1 (s), 142.7 (s), 144.2 

















25: -4.90 (c = 5.2 g/L, CHCl3) 
 IR: 1638 cm-1, 1702 cm-1 
 (mixture of two conformers in ratio 2:1) 
 
Major conformer   
1H-NMR (CDCl3) δ 0.45 (3H, d, J = 6.9 Hz), 3.04 (3H, s), 3.77 (1H, q, J 
= 6.9 Hz), 5.57 (1H, s), 5.76 (1H, s), 6.03 (1H, s), 
6.86 - 8.30 (8H, m) 
 
13C-NMR (CDCl3) δ 17.8 (q), 27.0 (q), 54.9 (d), 78.6 (d), 116.7 (dd, J2C-F 
= 23.2 Hz), 117.6 (dd, J2C-F = 23.0 Hz), 121.8 (t), 
127.4 (d), 128.0 (dd, J3C-F = 9.9 Hz), 128.4 (d), 
128.7 (d), 134.4 (d, J3C-F = 8.0 Hz), 137.5 (s), 140.7 




1H-NMR (CDCl3)  δ  1.27 (3H, d, J = 6.9 Hz), 2.86 (3H, s), 4.64 (1H, q, J 
= 6.9 Hz), 4.80 (1H, s), 5.25 (1H, s), 5.33 (1H, s), 
6.86 - 8.30 (8H, m) 
13C-NMR (CDCl3) δ 16.4 (q), 26.9 (q), 55.3 (d), 79.2 (d), 115.9 (dd, J2C-F 
= 23.4 Hz), 117.5 (dd, J2C-F = 22.9 Hz), 122.0 (t), 
127.3 (d), 127.7 (dd, J3C-F = 9.7 Hz), 128.4 (d), 
128.8 (d), 134.5 (d, J3C-F = 8.0 Hz), 136.3 (s), 140.6 
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25: -18.30 (c = 0.21 g/L, CHCl3) 
IR: 1665 cm-1, 1688 cm-1 
MS: m/z 393 (M+).  
(mixture of two conformers in ratio 3:1) 
 
Major conformer 
1H-NMR (CDCl3)  δ 0.92 (3H, d, J = 5.9 Hz), 1.11 (3H, d, J = 6.6 Hz), 
1.44 (1H, dqq, J = 5.9, 6.6, 9.2 Hz), 2.84 (3H, s), 
4.40 (1H, d J = 9.2 Hz), 4.86 (1H, s), 5.34 (1H, s), 
5.54 (1H, s), 6.92 - 6.94 (2H, m), 7.23 - 7.31 (3H, 
m), 7.31 - 7.38 (2H, m), 7.54 - 7.63 (1H, m), 8.16 - 
8.20 (1H, m) 
 
Minor conformer 
1H-NMR (CDCl3) δ 0.51(3H, d, J = 5.9 Hz), 0.63 (3H, d, J = 6.3 Hz), 
1.23 - 1.34 (1H, m), 2.94 (3H, s), 3.60 - 3.65 (1H, 
m), 5.54 (1H, s), 5.67 (1H, s), 6.18 (1H, s), 6.91 - 
8.24 (9H, m) 
 
1H-NMR (DMSO, T = 100°C)   δ 0.83 (3H, d, J =6.9 Hz), 0.89 (3H, d, J = 6.7 
Hz), 1.55 (1H, dqq, J = 6.7, 6.9, 7.3 Hz), 
2.77 (3H, s), 4.06 (1H, d, J = 7.3 Hz), 5.15 
(1H, s), 5.27 (1H, s), 5.71 (1H, s), 7.11 - 7.12 
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(2H, m), 7.13 - 7.31 (3H, m), 7.46 (1H, dd, J 
= 1.3, 7.5 Hz), 7.68 (1H, ddd, J = 1.3, 7.7, 
8.2 Hz), 7.76 (1H, ddd, J = 1.1, 7.5, 7.7 Hz), 
8.16 (1H, dd, J = 1.1, 8.2 Hz) 
 
13C-NMR (DMSO) δ 20.1 (q), 20.9 (q), 27.8 (d), 32.4 (q), 63.5 (d), 78.9 
(d), 120.6 (s), 122.6 (t), 125.7 (d), 128.7 (d), 128.9 
(d), 129.1 (d), 129.8 (d), 131.6 (d), 132.3 (s), 135.8 
















M.p. 145 °C 
 [α d]D
25: +55.70 (c = 13.0g/l, CHCl3) 
IR: 1644 cm-1, 1710 cm-1 
(mixture of two conformers in ratio 5:1) 
 
Major conformer 
1H-NMR (CDCl3) δ 0.88 (3H, d, J = 5.5 Hz), 1.09 (3H, d, J = 6.6 Hz), 
1.58 (1H, dqq, J = 5.5, 6.6, 8.9 Hz), 2.85 (3H, s), 
4.36 (1H, d J = 8.9 Hz), 4.91 (1H, s), 5.26 (1H, s), 
5.34 (1H, s), 6.95 - 8.07 (8H, m) 
 
13C-NMR (CDCl3) δ  19.4 (q), 19.7 (q), 27.2 (d), 32.2 (q), 63.3 (d), 78.6 
(d), 120.0 (s), 121.3 (t), 125.9 (d), 127.2 (d), 128.3 
(d), 128.6 (d), 128.8 (d), 130.4 (d), 133.4 (s), 137.1 
(s), 141.1 (s), 142.8 (s), 144.7 (s), 169.8 (s). 
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Minor conformer 
1H-NMR (CDCl3) δ 0.55 (3H, d, J = 5.6 Hz), 0.67 (3H, d, J = 5.9 Hz), 
1.20 - 1.26 (1H, m), 2.93 (3H, s), 3.57 - 3.63 (1H, 
m), 5.52 (1H, s), 5.62 (1H, s), 6.15 (1H, s), 6.95 - 
8.07 (8H, m) 
 
13C-NMR (CDCl3) δ 16.8 (q), 20.4 (q), 28.0 (d), 31.9 (q), 64.9 (d), 77.4 
(d), 120.0 (s), 121.3 (t), 126.3 (d), 127.8 (d), 128.1 
(d), 128.6 (d), 129.5 (d), 130.6 (d), 133.4 (s), 137.1 


















25: +0.24,  (c = 28.7 g/L, CHCl3) 
IR: 1640 cm-1, 1698 cm-1 
 (mixture of two conformers in ratio 4:1) 
 
Major conformers 
1H-NMR (CDCl3) δ 0.88 (3H, d, J = 5.9 Hz), 1.07 (3H, d, J = 6.6 Hz), 
1.55 (1H, dqq, J = 5.9, 6.6, 9.0 Hz), 2.82 (3H, s), 
4.33 (1H, d J = 9.0 Hz), 4.94 (1H, s), 5.24 (1H, s), 
5.35 (1H, s), 6.91 - 8.15 (8H, m) 
 
13C-NMR (CDCl3) δ 19.3 (q), 19.8 (q), 27.2 (d), 32.2 (q), 63.4 (d), 78.4 
(d), 116.6 (dd, J2C-F = 27.4 Hz), 117.4 (dd, J
2
C-F = 
23.1 Hz), 120.9 (t), 127.2 (d), 127.6 (dd, J3C-F = 9.4 
 63
Hz), 128.3 (d), 128.6 (d), 134.4 (d, J3C-F = 8.3 Hz), 
137.3 (s), 140.7 (s), 144.8 (s), 165.1 (d, J1C-F = 
259.7 Hz), 166.4 (s), 169.8 (s). 
 
Minor conformer  
1H-NMR (CDCl3) δ 0.49 (3H, d, J = 6.2 Hz), 0.64 (3H, d, J = 6.6 Hz), 
1.32 - 1.42 (1H, m), 2.89 (3H, s), 3.54 - 3.61 (1H, 
m), 5.48 (1H, s), 5.60 (1H, s), 6.12 (1H, s), 6.70 - 
8.29 (8H, m),  
 
13C-NMR (CDCl3) δ 16.6 (q), 20.4 (q), 28.0 (d), 31.8 (q), 64.8 (d), 77.3 
(d), 116.4 (dd, J2C-F = 27.2 Hz), 117.6 (dd, J
2
C-F = 
23.5 Hz), 120.0 (t), 127.2 (d), 127.8 (dd, J3C-F = 
9.0 Hz), 128.0 (d), 128.6 (d), 134.2 (d, J3C-F = 8.2 
Hz), 138.0 (s), 139.9 (s), 144.2 (s), 165.4 (d, J1C-F 


















25: +4.27, (c = 0.1 g/L, CHCl3) 
IR: 1658 cm-1, 1706 cm-1 
(mixture of two conformers in ratio 1:1) 
 
Major conformer 
1H-NMR (CDCl3) δ 2.46 - 2.52 (2H, m), 2.81 (3H, s), 3.10 (3H, s), 3.15 
- 3.22 (2H, m), 3.93 - 4.12 (1H, m), 4.17 (1H, s), 
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4.85 - 4.88 (1H, m), 5.17 (1H, s), 5.43 (1H, s), 5.59 
(1H, s), 5.71 (1H, s), 6.19 (1H, s), 6.48 - 7.92 (28H, 
m) 
 
13C-NMR (CDCl3) δ 26.9 (q), 27.6 (q), 36.8 (t), 39.0 (t), 60.5 (d), 61.4 
(d), 76.7 (d), 78.7 (d), 121.4 (t), 121.8 (t), 125.1 (d), 
125.7 (d), 126.2 (d), 127.0 (d),127.5 (d), 128.0 (d), 
128.2 (d), 128.3 (d), 128.4 (d), 128.5 (d, overlap), 
128.6 (d), 129.3 (d), 129.4 (d), 129.8 (d), 130.0 (d), 
130.3 (d), 130.4 (d), 130.8 (d), 132.4 (d), 133.0 (d), 
136.1 (s), 136.9 (s), 137.2 (s), 137.4 (s), 141.1 (s), 
141.4 (s), 142.5 (s), 142.7 (s), 143.9 (s), 144.0 (s), 

















Pale yellow crystals 
M.P. 75°C 
[α d]D
25: +4.37, (c = 11.9 g/L, CHCl3) 
IR: 1636 cm-1, 1688 cm-1 
(mixture of two conformers in ratio 1:1) 
 
1H-NMR (CDCl3) δ 2.79 (3H, s), 2.84 - 2.95 (2H, m), 3.07 (3H,s), 3.12 - 
3.20 (2H, m), 3.93 - 4.15 (1H, m), 4.21 (1H, s), 4.80 - 
4.86 (1H, m), 5.16 (1H, s), 5.44 (1H, s), 5.57 (1H, s), 
5.68 (1H, s), 6.18 (1H, s), 6.47 - 6.51 (2H, m), 6.75 - 
7.48 (22H, m), 7.84 - 7.96 (2H, m),  
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13C-NMR (CDCl3) δ 26.9 (q), 27.6 (q), 36.8 (t), 39.0 (t), 60.5 (d), 61.4 
(d), 76.9 (d), 78.6 (d), 121.5 (t), 121.7 (t),125.7 (d), 
126.1 (d), 126.3 (d), 126.9 (d),127.2 (d), 128.2 (d), 
128.3 (d), 128.4(d), 128.5 (d), 128.6 (d, overlap), 
128.7 (d), 129.4 (d), 129.7 (d), 129.8 (d), 130.0 (d), 
130.3 (d), 130.4 (d), 132.4 (s), 133.0 (s), 136.1 (s), 
136.9 (s), 137.2 (s), 137.7 (s), 141.0 (s), 141.2 (s), 
142.4 (s), 142.5 (s), 144.0 (s), 168.6 (s), 168.7 (s), 



















25: -4.01,  (c = 19.1 g/L, CHCl3) 
IR: 1660 cm-1, 1700 cm-1 
(mixture of two conformers in ratio 1:1) 
  
1H-NMR (CDCl3)  δ 2.48 - 2.56 (2H, m), 2.79 (3H, s), 3.08 (3H, s), 3.01 
- 3.20 (2H, m), 3.92 - 4.13 (1H, m), 4.21 (1H, s), 
4.82 - 4.89 (1H, m), 5.15 (1H, s), 5.44 (1H, s), 5.58 
(1H, s), 5.69 (1H, s), 6.21 (1H, s), 6.25 - 6.42 (1H, 
m), 6.48 - 6.51 (2H, m), 6.75 - 7.08 (6H, m), 7.25 - 
7.48 (10H, m), 7.98 - 8.05 (2H, m) 
 
13C-NMR (CDCl3) δ 26.9 (q), 27.6 (q), 36.8 (t), 39.1 (t), 60.6 (d), 61.5 
(d), 76.7 (d), 78.6 (d), 116.0 (dd, J2C-F = 21.8 Hz), 
116.2 (dd, J2C-F = 22.0 Hz), 117.1 (dd, J
2
C-F = 21.6 
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Hz), 117.4 (dd, J2C-F = 21.9 Hz), 121.3 (t), 121.7 (t), 
126.2 (d), 126.8 (dd, J3C-F = 11.6 Hz), 127.4 (dd, 
J3C-F = 11.0 Hz), 128.4 (d), 128.6 (d, overlap), 130.0 
(d), 133.5 (d, J3C-F = 5.6 Hz), 134.3 (d, J
3
C-F = 6.2 
Hz), 136.3 (s), 136.6 (s), 136.7 (s), 137.0 (s), 137.4 
(s), 137.7 (s), 144.0 (s), 144.2 (s), 165.1 (d, J1C-F = 
231.6 Hz), 166.4 (s), 167.6 (d, J1C-F = 259.3 Hz), 
168.7 (s), 168.8 (s), 169.1 (s). 
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46 a-c 47 a-c
Fe, AcOH
EtOH
  a R = Me, b R = i-Pr, c R = Bn  
 
A solution of 46 (1.04 mmol) in EtOH (10 mL) and 20% aq. AcOH (2.5 mL) was 
treated with Fe powder (0.464 g, 8.32 mmol), and refluxed for 5 hours under 
vigorous stirring. The mixture was diluted with AcOEt (50 mL) and filtered over a 
celite pad. The filtrate was washed with aq. NaHCO3 (50 mL) and with water (2 × 
25 mL), then the organic layer was dried over Na2SO4. The solvent was 
evaporated under reduced pressure and the products purified on column 




































25 : +25.3  (c = 0.22 g/L, CHCl3) 
IR: 1648 cm-1, 1698 cm-1, 3488 cm-1 
1H-NMR (CDCl3) δ 0.66 (3H, d, J = 6.9 Hz), 2.96 (3H, s), 4.13 (2H, br 
s), 4.30 (1H, q, J = 6.9 Hz), 5.36 (2H, s), 5.87 (1H, 
s), 6.70 - 6.75 (2H, m), 7.00 - 7.35 (7H, m) 
 
13C-NMR (CDCl3) δ 17.3 (q), 27.5 (q), 55.9 (d), 79.5 (d), 117.1 (d), 
118.2 (d), 119.2 (s), 121.3 (s), 121.8 (t), 127.2 (d), 
127.6 (d), 128.8 (d), 128.9 (d), 131.4 (d), 137.8 (s), 




























m.p: 106° C 
 [αd]D
25 : +21.4  (c = 24.1 g/L, CHCl3) 
IR: 1636 cm-1, 1694 cm-1, 3448 cm-1 
 
1H-NMR (CDCl3) δ 0.55 (3H, d, J = 6.6 Hz), 2.80 (3H, s), 4.15 (1H, q, J 
= 6.6 Hz), 4.26 (2H, br s), 5.16 (1H, s), 5.20 (1H, 
s), 5.68 (1H, s), 6.51 - 6.54 (1H, m), 6.90 - 6.97 
(4H, m), 7.13 - 7.21 (3H, m) 
 
13C-NMR (CDCl3) δ 16.6 (q), 26.9 (q), 55.2 (d), 79.0 (d), 117.4 (d), 
121.4 (t), 121.5 (s), 121.6 (s), 126.5 (d), 128.0 (d), 
128.3 (d), 128.4 (d), 130.6 (d), 137.1 (s), 143.1 (s), 


















25 : +9.87 (c = 2.43 g/L, CHCl3) 
IR: 1654 cm-1, 1702 cm-1, 3450 cm-1 
 
1H-NMR (CDCl3) δ 0.67 (3H, d, J = 7.0 Hz), 2.96 (3H, s), 3.87 (2H, br 
s), 4.12 (1H, q, J = 7.0 Hz), 5.37 (2H, s), 5.82 (1H, 
s), 6.61 - 7.35 (8H, m) 
 
13C-NMR (CDCl3) δ 17.2 (q), 27.4 (q), 55.7 (d), 79.4 (d), 113.8 (dd, J2C-F 
= 23.7 Hz), 118.1 (dd, J2C-F = 22.1 Hz), 118.3 (dd, 
J3C-F = 7.2 Hz), 121.9 (t), 122.0 (d, J
3
C-F = 6.6 Hz), 
128.6 (d), 128.8 (d), 129.0 (d), 137.5 (s), 140.7 (s), 






























25: +56.1  (c = 0.38 g/L  in CHCl3) 
IR: 1640 cm-1, 1690 cm-1, 3492 cm-1 
 
1H-NMR (CDCl3) δ 0.75 (3H, d, J = 6.8 Hz), 0.97 (3H, d, J = 6.5 Hz), 
1.26 - 1.29 (1H, qqd, J = 6.5, 6.8, 9.1 Hz), 2.81 
(3H, s), 4.15 (2H, br s), 4.35 (1H, d, J = 9.1 Hz), 
5.24 (1H, s), 5.36 (1H, s), 5.64 (1H, s), 6.70 - 6.75 
(2H, m), 7.13 - 7.34 (7H, m) 
 
13C-NMR (CDCl3) δ 19.3 (q), 20.6 (q), 28.0 (d), 32.6 (q), 63.6 (d), 79.5 
(d), 117.1 (d), 117.7 (d), 120.7 (s), 121.2 (t), 128.2 
(d), 128.4 (d), 128.7 (d), 128.8 (d), 131.7 (d), 138.3 





























25: +63.7  (c = 12.0 g/L in CHCl3) 
IR: 1654 cm-1, 1706 cm-1, 3466 cm-1 
 
1H-NMR CDCl3) δ 0.67 (3H, d, J = 6.6 Hz), 0.96 (3H, d, J = 6.3 Hz), 
1.23 - 1.25 (1H, m), 2.78 (3H, s), 4.30 (2H, br s), 
4.32 - 4.36 (1H, m), 5.15 (1H, s), 5.36 (1H, s), 5.51 
(1H, s),  6.63 - 6.65 (1H, m), 7.11 - 7.31 (7H, 
m) 
 
13C-NMR (CDCl3) δ 19.0 (q), 20.0 (q), 27.5 (d), 32.1 (q), 62.9 (d), 79.5 
(d), 117.8 (d), 120.9 (s), 121.5 (t), 121.9 (s), 127.9 
(d), 128.0 (d), 128.4 (d), 128.5 (d), 131.0 (d), 137.4 



























M.P.: 44° C 
 [αd]D
25: +26.7 (c = 21.8 g/L, CHCl3) 
IR: 1640 cm-1, 1696 cm-1, 3438 cm-1 
 
1H-NMR (CDCl3) δ 0.73 (3H, d, J = 6.8 Hz), 0.97 (3H, d, J = 6.5 Hz), 
1.32 (1H, qqd, J = 6.5, 6.8, 9.0 Hz), 2.83 (3H, s), 
3.47 (2H, br s), 4.29 (1H, d, J = 9.0 Hz), 5.20 (1H, 
s), 5.36 (1H, s), 5.60 (1H, s), 6.65 - 7.35 (8H, m) 
 
13C-NMR (CDCl3) δ 18.8 (q), 20.1 (q), 27.5 (d), 32.1 (q), 63.1 (d), 78.9 
(d), 114.3 (dd, J2C-F = 23.8 Hz), 117.7 (dd, J
3
C-F = 
8.1 Hz), 117.8 (dd, J2C-F = 20.2 Hz), 120.9 (t), 121.2 
(d, J3C-F = 6.1 Hz), 127.9 (d), 128.3 (d), 128.4 (d), 
137.6 (s), 140.8 (s), 145.2 (s), 154.8 (d, J1C-F = 















M.p. 130 °C 
 [αd]D
25 : +139  (c = 0.28 g/L, CHCl3) 
IR: 1642 cm-1, 1696 cm-1, 3472 cm-1 
 
1H-NMR (CDCl3) δ 1.87 - 1.94 (1H, m), 2.37 - 2.43 (1H, m), 2.93 (3H, 
s), 4.01 (2H, br s), 4.50 - 4.54 (1H, m), 5.19 (1H, s), 
5.46 (1H, s), 5.80 (1H, s), 6.71 - 7.40 (14H, m) 
 
13C-NMR (CDCl3) δ 27.5 (q), 38.7 (t), 60.5 (d), 79.0 (d), 117.2 (d), 118.3 
(d), 121.1 (s), 121.7 (t), 126.8 (d), 127.4 (d), 128.5 
(d), 128.8 (d, overlap), 128.9 (d), 129.8 (d), 131.5 
(d), 137.4 (s), 138.0 (s), 144.8 (s), 145.0 (s), 169.9 





























Yellow oil  
 [αd]D
25: +13.69  (c = 8.47 g/L in CHCl3) 
IR: 1650 cm-1, 1696 cm-1, 3480 cm-1 
 
1H-NMR (CDCl3) δ 2.03 - 2.36 (2H, m), 2.93 (3H, s), 4.15 (2H, br s), 
4.56 - 4.60 (1H, m), 5.12 (1H, s), 5.36 (1H, s), 5.70 
(1H, s), 6.58 - 7.41 (13H, m) 
 
13C-NMR (CDCl3) δ 27.1 (q), 38.2 (t), 60.0 (d), 78.9 (d), 113.4 (d), 118.0 
(d), 121.4 (s), 121.7 (t), 122.4 (s), 126.6 (d), 127.1 
(d), 128.2 (d), 128.4 (d), 128.6 (d), 129.3 (d), 129.4 
(d), 130.9 (d), 131.3 (d), 136.9 (s), 137.3 (s), 143.2 





























M.p: 142° C 
 [αd]D
25: +4.734  (c = 5.07 g/L, CHCl3) 
IR (nujol): 1662 cm-1, 1708 cm-1, 3490 cm-1 
 
1H-NMR (CDCl3) δ 2.03 - 2.36 (2H, m), 2.93 (3H, s), 4.15 (2H, br s), 
4.56 - 4.60 (1H, m), 5.12 (1H, s), 5.36 (1H, s), 5.70 
(1H, s), 6.58 - 7.41 (13H, m) 
 
13C-NMR (CDCl3) δ 27.1 (q), 38.2 (t), 60.0 (d), 78.6 (d), 113.7 (dd, J2C-F 
= 23.7 Hz), 117.9 (dd, J2C-F = 22.6 Hz), 118.1 (dd, 
J3C-F = 7.4 Hz), 121.5 (t), 121.2 (d, J
3
C-F = 6.1 Hz), 
126.6 (d), 128.2 (d), 128.4 (d), 128.6 (d, overlap), 
129.4 (d), 137.6 (s), 137.4 (s), 140.4 (s), 144.4 (s), 
155.2 (d, J1C-F = 236.8 Hz), 168.6 (s), 169.4 (s). 
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39 a-c 40 a-c
MeOH
NaNO2, HCl
  a R = Me, b R = i-Pr, c R = Bn  
 
To a solution of 47 (1.13 mmol) in MeOH (2 mL) and 6M HCl (0.65 mL) cooled 
at 0° C NaNO 2 (0.156 g, 2.26 mmol) was added portionwise. After 30 minutes 
AcONa was added until pH 5, then a solution of ethyl 2-chloroacetoacetate (1.13 
mmol, 0.122 mL) in MeOH (1 mL) was dropped under vigorous stirring at room 
temperature for 24 hours. The solvent was evaporated under reduced pressure 
and the residue extracted with Et2O (2 × 15 mL). The organic layer was washed 
with aq. NaHCO3 (15 mL) and with water (30 mL), then dried over Na2SO4. The 
solvent was evaporated under reduced pressure and the products purified on 
silica gel column chromatography with light (EdP/AcOEt 1:1). 
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Ethyl (2 R,5S)-2-chloro-2- {2-[2-(3,5-dimethyl-4-oxo-2-(1-

















M.p.: 65° C 
 [αd]D
25 : +2.1 (c = 0.15 g/L, CHCl3) 
IR: 1650 cm-1, 1703 cm-1, 1716 cm-1, 3338 cm-1 
 
1H-NMR (CDCl3) δ 0.62 (3H, d, J = 6.6 Hz), 1.42 (3H, t, J = 7.1 Hz), 
2.98 (3H, s), 4.35 (1H, q, J = 6.6 Hz), 4.41 (2H, q, J 
= 7.1 Hz), 5.38 (1H, s), 5.40 (1H, s), 5.91 (1H, s), 
7.00 - 7.61 (9H, m), 9.40 (1H, s) 
 
13C-NMR (CDCl3) δ 14.6 (q), 17.1 (q), 27.5 (q), 56.2 (d), 63.3 (t), 79.9 
(d), 116.7 (d), 118.5 (s), 121.0 (s), 122.1 (t), 122.4 
(d), 127.3 (d), 128.8 (d), 128.9 (d), 132.1 (d), 132.2 
(d), 137.4 (s), 140.3 (s), 144.7 (s), 159.2 (s), 168.5 













Ethyl (2 R,5S)-2-chloro-2- {2-[4-chloro-2-(3,5-dimethyl-4-oxo-2-(1-


















M.p.: 174° C 
 [αd]D
25 : +2.421  (c = 17.8 g/L, CHCl3) 
IR: 1646 cm-1, 1694 cm-1, 1728 cm-1, 3392 cm-1 
 
1H-NMR (CDCl3) δ 0.66 (3H, d, J = 6.5 Hz), 1.37 (3H, t, J = 6.9 Hz), 
2.94 (3H, s), 4.31 - 4.37 (3H, m), 5.37 (2H, s), 5.83 
(1H, s), 7.04 - 7.47 (8H, m), 9.33 (1H, s) 
 
13C-NMR (CDCl3) δ 14.2 (q), 16.7 (q), 27.0 (q), 55.6 (d), 63.0 (t), 79.6 
(d), 117.8 (d), 118.6 (s), 121.7 (s), 121.8 (s), 121.9 
(t), 127.0 (d), 128.3 (d), 128.5 (d), 128.6 (d), 131.4 
(d), 136.8 (s), 138.4 (s), 144.1 (s), 159.1 (s), 167.0 
































Yield: 49%  
Yellow crystals 
m.p.: 125° C 
 [αd]D
25 : -0.347  (c = 10.3 g/L, CHCl3) 
IR: 1642 cm-1, 1708 cm-1, 1732 cm-1, 3412 cm-1 
 
1H-NMR (CDCl3) δ 0.64 (3H, d, J = 6.3 Hz), 1.39 (3H, t, J = 7.1 Hz), 
2.96 (3H, s), 4.30 (1H, q, J = 6.3 Hz), 4.37 (2H, q, J 
= 7.1 Hz), 5.38 (2H, s), 5.86 (1H, s), 6.95 - 7.51 
(8H, m), 9.22 (1H, s) 
 
13C-NMR (CDCl3) δ 14.2 (q), 16.7 (q), 27.0 (q), 55.7 (d), 62.9 (t), 79.4 
(d), 113.8 (dd, J2C-F = 24.3 Hz), 118.0 (s), 118.2 
(dd, J3C-F = 7.5 Hz), 118.5 (dd, J
2
C-F = 22.4 Hz), 
121.8 (t), 128.3 (d), 128.5 (d), 128.6 (d), 136.1 (s), 
136.8 (s), 140.6 (s), 144.1 (s), 157.5 (d, J1C-F = 





























m.p.: 69° C 
 [αd]
D
25: +45.6 (c = 0.4 g/L, CHCl3) 
IR: 1656 cm-1, 1688 cm-1, 1724 cm-1, 3436 cm-1 
 
1H-NMR (CDCl3) δ 0.72 (3H, d, J = 6.8 Hz), 0.98 (3H, d, J = 6.5 Hz), 
1.17 - 1.21 (1H, m), 1.43 (3H, t, J = 7.1 Hz), 2.83 
(3H, s), 4.39 – 4.45 (3H, m), 5.32 (1H, s), 5.42 (1H, 
s), 5.68 (1H, s), 7.01 (1H, dd, J = 7.4, 7.5 Hz), 7.10 
- 7.13 (2H, m), 7.27 - 7.36 (3H, m), 7.40 (1H, d, J = 
7.5 Hz), 7.45 (1H, dd, J = 7.4, 8.2 Hz), 7.64 (1H, d, 
J = 8.2 Hz), 9.51 (1H, br s)  
 
13C-NMR (CDCl3) δ 14.6 (q), 19.3 (q), 20.5 (q), 28.0 (d), 32.6 (q), 63.3 
(t), 63.8 (d), 79.7 (d), 116.7 (d), 118.9 (s), 120.6 (s), 
121.4 (t), 122.0 (d), 128.2 (d), 128.3 (d), 128.9 (d), 
129.0 (d), 132.4 (d), 138.1 (s), 140.8 (s), 145.8 (s), 
159.9 (s), 170.3 (s), 171.2 (s). 
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Ethyl (2 R,5S)-2-chloro-2- {2-[4-chloro-2-(5-isopropyl-3-methyl-4-oxo-2-(1-

















Pale yellow oil 
 [αd]D
25: -0.806  (c = 6.2 g/L, CHCl3) 
IR: 1634 cm-1, 1686 cm-1, 1716 cm-1, 3424 cm-1 
 
1H-NMR (CDCl3) δ 0.62 (3H, d, J = 6.6 Hz), 0.91 (3H, d, J = 6.4 Hz), 
1.00 - 1.09 (1H, m), 1.33 (3H, t, J = 7.1 Hz), 2.77 
(3H, s), 4.27 - 4.35 (3H, m), 5.18 (1H, s), 5.36 (1H, 
s), 5.53 (1H, s), 7.05 - 7.48 (8H, m), 9.49 (1H, s)  
 
13C-NMR (CDCl3) δ 14.1 (q), 18.9 (q), 19.9 (q), 27.4 (d), 32.0 (q), 62.9 
(t), 63.0 (d), 79.6 (d), 117.7 (d), 118.8 (s), 121.2 (s), 
121.7 (t), 126.7 (s), 127.8 (d), 127.9 (d), 128.3 (d), 
128.5 (d), 131.6 (d), 137.2 (s), 138.9 (s), 145.0 (s), 















Ethyl (2 R,5S)-2-chloro-2- {2-[4-fluoro-2-(5-isopropyl-3-methyl-4-oxo-2-(1-
















Yield: 57%  
Colorless oil 
 [αd]D
25: +16.38  (c = 5.0 g/L, CHCl3) 
IR: 1638 cm-1, 1710 cm-1, 1722 cm-1, 3384 cm-1 
 
1H-NMR (CDCl3) δ 0.70 (3H, d, J = 6.8 Hz), 0.97 (3H, d, J = 6.5 Hz), 
1.18 - 1.23 (1H, m), 1.40 (3H, t, J = 7.1 Hz), 2.83 
(3H, s), 4.33 - 4.41 (3H, m), 5.29 (1H, s), 5.42 (1H, 
s), 5.64 (1H, s), 7.08 - 7.17 (4H, m), 7.27 - 7.33 
(3H, m), 7.53 - 7.57 (1H, m), 9.30 (1H, br s) 
 
13C-NMR (CDCl3) δ 14.2 (q), 18.9 (q), 20.3 (q), 27.5 (d), 32.1 (q), 62.9 
(t), 63.3 (d), 79.2 (d), 114.7 (dd, J2C-F = 24.4 Hz), 
118.1 (dd, J3C-F = 7.4 Hz), 118.5 (s), 118.8 (dd, J
2
C-F 
= 22.3 Hz), 121.3 (t), 127.8 (d), 128.6 (d), 128.9 
(d), 136.6 (s), 137.3 (s), 140.0 (s), 145.2 (s), 157.2 































25: -33.79  (c = 0.21 g/L, CHCl3) 
IR: 1646 cm-1, 1692 cm-1, 1720 cm-1, 3404 cm-1 
MS: m/z 544 (M+). 
 
1H-NMR (CDCl3) δ 1.42 (3H, t, J = 7.1 Hz), 2.01 - 2.05 (1H, m), 2.08 - 
2.13 (1H, m), 2.98 (3H, s), 4.41 (2H, q, J = 7.1 Hz), 
4.60 (1H, t, J = 4.7 Hz), 5.23 (1H, s), 5.37 (1H, s), 
5.83 (1H, s), 6.75 - 7.56 (14H, m), 9.31 (1H, br s) 
 
13C-NMR (CDCl3) δ 14.6 (q), 27.5 (q), 38.7 (t), 60.9 (d), 63.3 (t), 79.4 
(d), 116.8 (d), 118.5 (s), 120.9 (s), 122.0 (t), 122.4 
(d), 126.5 (d), 126.9 (d), 127.5 (d), 128.6 (d), 128.8 
(d), 129.3 (d), 129.7 (d), 132.1 (d), 136.8 (s), 137.8 


































25: +0.022  (c = 4.49 g/L, CHCl3) 
IR: 1650 cm-1, 1702 cm-1, 1726 cm-1, 3456 cm-1 
 
1H-NMR (CDCl3) δ 1.41 (3H, t, J = 7.1 Hz), 2.22 - 2.26 (2H, m), 2.98 
(3H, s), 4.40 (2H, q, J = 7.1 Hz), 4.65 (1H, t, J = 6.4 
Hz), 5.19 (1H, s), 5.40 (1H, s), 5.79 (1H, s), 6.77 - 
6.80 (2H, m), 7.10 - 7.43 (11H, m), 9.24 (1H, br s) 
 
13C-NMR (CDCl3) δ 14.2 (q), 27.1 (q), 38.3 (t), 60.3 (d), 63.0 (t), 79.3 
(d), 117.8 (d), 118.7 (s), 121.3 (s), 122.0 (t), 126.6 
(d), 127.0 (s), 127.1 (d), 128.3 (d), 128.7 (d), 128.8 
(d, overlapped), 129.1 (d), 130.2 (d), 131.5 (d), 
136.3 (s), 137.3 (s), 138.6 (s), 144.2 (s), 159.2 (s), 
































m.p.: 105° C 
[αd]
D
25 : -0.13   (c = 4.43 g/L, CHCl3) 
IR: 1647 cm-1, 1704 cm-1, 1728 cm-1, 3462 cm-1 
 
1H-NMR (CDCl3) δ 1.40 (3H, t, J = 7.1 Hz), 2.17 - 2.25 (2H, m), 2.96 
(3H, s), 4.39 (2H, q, J = 7.1 Hz), 4.60 (1H, t, J = 6.4 
Hz), 5.17 (1H, s), 5.37 (1H, s), 5.83 (1H, s), 6.78 - 
7.44 (13H, m), 9.12 (1H, br s) 
 
3C-NMR (CDCl3) δ 14.2 (q), 27.1 (q), 38.3 (t), 60.4 (d), 63.0 (t), 79.0 
(d), 114.1 (dd, J2C-F = 24.3 Hz), 118.0 (s), 118.3 
(dd, J3C-F = 7.5 Hz), 118.5 (dd, J
2
C-F = 22.4 
Hz),121.5 (s), 121.8 (t), 126.6 (d), 128.2 (d), 128.3 
(d, overlapped), 128.6 (d), 129.2 (d), 136.1 (s), 
136.3 (s), 137.3 (s), 144.2 (s), 157.4 (d, J1C-F = 
243.0 Hz), 159.3 (s), 167.3 (s), 169.1 (s). 
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48 a-c 50 a-c
TEA
Toluene
  a R = Me, b R = i-Pr, c R = Bn  
 
A solution of 41 (0.2 mmol) in toluene (9 mL) was treated with TEA (0.11 mL, 
0.8 mmol) and refluxed for 24 hours. The organic layer was washed with aq. 
NaHCO3 (10 mL) and with water (20 mL), then it was dried over Na2SO4. The 
solvent was evaporated under reduced pressure and the products purified on 






































M.p.: 90° C 
 [αd]D
25: +667 (c = 0.20 g/L, CHCl3) 
IR: 1652 cm-1, 1705 cm-1, 1716 cm-1 
 
1H-NMR (CDCl3) δ 0.32 (3H, d, J = 6.8 Hz), 1.37 (3H, t, J = 7.1 Hz), 
3.25 (3H, s), 3.60 (1H, d, J = 16.1 Hz), 3.82 (1H, d, 
J = 16.1 Hz), 4.25 (1H, q, J = 6.8 Hz), 4.33 (2H, q, 
J = 7.1 Hz), 5.57 (1H, s), 7.13 (1H, dd, J = 7.4, 8.0 
Hz), 7.18 - 7.21 (2H, m), 7.36 - 7.38 (3H, m), 7.52 
(1H, ddd, J = 1.6, 7.4, 8.7 Hz), 7.84 (1H, d, J = 8.7 
Hz), 8.11 (1H, dd, J = 1.6, 8.0 Hz) 
 
13C-NMR (CDCl3) δ 14.2 (q), 14.6 (q), 30.5 (q), 44.7 (t), 55.9 (d), 62.4 
(t), 77.4 (d), 81.7 (s), 116.8 (s), 118.1 (d), 122.4 (d), 
126.5 (d), 129.5 (d), 129.9 (d), 133.3 (d), 134.0 (d), 




























m.p.: 143° C 
[αd]D
25: +89.697  (c = 2.31 g/L, CHCl3) 
IR: 1647 cm-1, 1704 cm-1, 1728 cm-1 
 
1H-NMR (CDCl3) δ 0.32 (3H, d, J = 6.7 Hz), 1.33 (3H, t, J = 7.0 Hz), 
3.21 (3H, s), 3.57 (1H, d, J = 16.1 Hz), 3.82 (1H, d, 
J = 16.1 Hz), 4.17 (1H, q, J = 6.7 Hz), 4.28 (2H, q, 
J = 7.0 Hz), 5.53 (1H, s), 7.11 - 7.40 (6H, m), 7.76 - 
7.79 (1H, m), 8.04 (1H, s) 
 
13C-NMR (CDCl3) δ 13.7 (q), 14.2 (q), 30.1 (q), 44.4 (t), 55.5 (d), 62.1 
(t), 76.7 (d), 81.1 (s), 117.2 (s), 119.3 (d), 126.6 (d), 
127.2 (s), 129.1 (d), 129.6 (d), 132.1 (d), 133.4 (d), 





























m.p.: 145° C 
Yield: 71% 
[αd]D
25: +912.07  (c = 3.23 g/L, CHCl3) 
IR: 1655 cm-1, 1690 cm-1, 1724 cm-1 
 
1H-NMR (CDCl3) δ 0.29 (3H, d, J = 6.7 Hz), 1.35 (3H, t, J = 7.1 Hz), 
3.24 (3H, s), 3.58 (1H, d, J = 16.1 Hz), 3.82 (1H, d, 
J = 16.1 Hz), 4.21 (1H, q, J = 6.7 Hz), 4.31 (2H, q, 
J = 7.1 Hz), 5.54 (1H, s), 7.15 - 7.40 (6H, m), 7.78 - 
7.83 (2H, m).  
 
13C-NMR (CDCl3) δ 13.7 (q), 14.2 (q), 30.1 (q), 44.4 (t), 55.6 (d), 62.0 
(t), 76.7 (d), 81.1 (s), 118.1 (s), 118.1 (d), 118.3 
(dd, J2C-F = 24.6 Hz), 119.7 (dd, J
3
C-F = 6.7 Hz), 
121.1 (dd, J2C-F = 22.7 Hz), 126.7 (d), 129.1 (d), 
129.2 (d), 129.4 (d), 129.6 (d), 137.4 (s), 137.5 (s), 
142.9 (s), 157.8 (d, J1C-F = 240.7 Hz), 161.5 (s), 




















m.p.: 138° C 
 [αd]D
25: +975 (c = 0.38 g/L, CHCl3) 
IR: 1644 cm-1, 1702 cm-1, 1720 cm-1 
 
1H-NMR (CDCl3) δ 0.16 (1H, qqd J = 6.6, 6.7, 9.8 Hz), 0.45 (3H, d, J = 
6.7 Hz), 0.81 (3H, d, J = 6.6 Hz), 1.36 (3H, t, J = 
7.1 Hz), 3.20 (3H, s), 3.55 (1H, d, J = 15.9 Hz), 
3.76 (1H, d, J = 15.9 Hz), 4.04 (1H, d, J = 9.8 Hz), 
4.32 (2H, q, J = 7.1 Hz), 5.42 (1H, s), 7.12 (1H, dd, 
J = 7.3, 8.1 Hz), 7.26 - 7.37 (5H, m), 7.50 (1H, ddd, 
J = 1.6, 7.3, 8.6 Hz), 7.80 (1H, d, J = 8.6 Hz), 8.19 
(1H, dd, J = 1.6, 8.1 Hz) 
 
13C-NMR (CDCl3) δ 14.6 (q), 19.3 (q), 22.2 (q), 30.1 (d), 33.3 (q), 45.0 
(t), 62.5 (t), 63.5 (d), 79.9 (d), 81.1 (s), 116.7 (s), 
118.5 (d), 122.4 (d), 127.7 (d), 129.3 (d), 129.7 (d), 
133.7 (d), 134.4 (d), 137.8 (s), 142.3 (s), 145.6 (s), 




















m.p.: 135° C 
 [αd]D
25: +818 (c = 3.94 g/L, CHCl3) 
IR: 1652 cm-1, 1688 cm-1, 1716 cm-1 
 
1H-NMR (CDCl3) δ 0.18 (1H, qqd J = 6.6, 6.5, 9.7 Hz),  0.42 (3H, d, J = 
6.7 Hz), 0.80 (3H, d, J = 6.5 Hz), 1.36 (3H, t, J = 
7.2 Hz), 3.20 (3H, s), 3.56 (1H, d, J = 16.1 Hz), 
3.76 (1H, d, J = 16.1 Hz), 4.03 (1H, d, J = 9.7 Hz), 
4.32 (2H, q, J = 7.2 Hz), 5.42 (1H, s), 7.22 - 7.44 
(6H, m), 7.79 (1H, d, J = 9.1 Hz), 8.18 (1H, s) 
 
13C-NMR (CDCl3) δ 14.2 (q), 18.9 (q), 21.7 (q), 29.8 (d), 32.9 (q), 44.7 
(t), 62.2 (t), 63.2 (d), 76.5 (d), 80.6 (s), 117.1 (s), 
119.7 (d), 127.1 (d), 127.4 (s), 129.0 (d), 129.4 (d), 
132.6 (d), 133.8 (d), 137.1 (s), 140.4 (s), 145.3 (s), 


















 Yield: 46% 
Yelow crystal 
M.p: 144° C 
[αd]D
25: +207.4 (c = 2.23 g/L, CHCl3) 
IR: 1644 cm-1, 1701 cm-1, 1733 cm-1 
 
1H-NMR (CDCl3) δ 0.07 (3H, d, J = 6.6 Hz), 0.45 (1H, qqd J = 6.6, 6.5, 
9.1 Hz), 0.82 (3H, d, J = 6.5 Hz), 1.22 (3H, t, J = 
7.2 Hz), 3.19 (3H, s), 3.53 (1H, d, J = 16.0 Hz), 
3.75 (1H, d, J = 16.0 Hz), 4.02 (1H, d, J = 9.1 Hz), 
4.31 (2H, q, J = 7.2 Hz), 5.32 (1H, s), 7.10 - 7.83 
(8H, m) 
 
13C-NMR (CDCl3) δ 14.2 (q), 18.9 (q), 21.9 (q), 29.7 (d), 32.8 (q), 44.5 
(t), 62.1 (t), 63.1 (d), 76.5 (d), 81.2 (s), 114.5 (d), 
118.7 (d), 119.3 (dd, J2C-F = 23.7 Hz), 120.0 (dd, 
J3C-F = 7.5 Hz), 122.6 (d), 125.2 (dd, J
2
C-F = 22.4 
Hz), 127.2 (d), 127.3 (d), 137.5 (s), 137.8 (s), 143.2 























25: +94.6 (c = 0.20 g/L, CHCl3) 
IR: 1643 cm-1, 1691 cm-1, 1735 cm-1 
 
1H-NMR (CDCl3) δ 0.82 - 0.91 (1H, m), 1.39 (3H, t, J = 7.1 Hz), 2.34 - 
2.38 (1H, m), 3.24 (3H, s), 3.64 (1H, d, J = 16.1 
Hz), 3.84 (1H, d, J = 16.1 Hz), 4.31 (2H, q, J = 7.1 
Hz), 5.56 (1H, s), 7.15 - 8.16 (14H, m)  
 
13C-NMR (CDCl3) δ 14.6 (q), 28.7 (q), 35.0 (t), 44.7 (t), 60.6 (d), 60.8 
(t), 76.8 (d), 81.7 (s), 116.8 (s), 118.2 (d), 122.5 (d), 
126.8 (d), 127.5 (d), 128.5 (d), 129.6 (d), 129.8 (d), 
130.2 (d), 133.3 (d), 134.1 (d), 137.9 (s), 138.3 (s), 






























Yellow crystal  
M.p: 141° C 
 [αd] : +914  (c = 1.89 g/L in CHCl3) 
IR: 1641 cm-1, 1708 cm-1, 1722 cm-1 
 
1H-NMR (CDCl3) δ 0.86 - 0.92 (1H, m), 1.37 (3H, t, J = 7.2 Hz), 2.18 - 
2.26 (1H, m), 3.23 (3H, s), 3.64 (1H, d, J = 16.1 
Hz), 3.83 (1H, d, J = 16.1 Hz), 4.35 (2H, q, J = 7.2 
Hz), 5.52 (1H, s), 7.13 - 8.13 (13H, m) 
  
13C-NMR (CDCl3) δ 14.2 (q), 30.3 (q), 34.6 (t), 44.5 (t), 60.3 (d), 62.2 
(t), 76.3 (d), 81.1 (s), 117.2 (s), 119.4 (d), 126.5 (d), 
126.9 (d), 127.7 (s), 128.2 (d), 129.2 (d), 129.3 (d), 
129.9 (d), 132.2 (d), 133.6 (d), 137.2 (s), 137.8 (s), 






























M.p: 146° C 
 [αd]D
25: +0.643  (c = 2.2 g/L, CHCl3) 
IR: 1646 cm-1, 1692 cm-1, 1734 cm-1 
 
1H-NMR (CDCl3) δ 0.82 - 0.88 (1H, m), 1.37 (3H, t, J = 7.1 Hz), 2.30 - 
2.35 (1H, m), 3.23 (3H, s), 3.62 (1H, d, J = 16.0 
Hz), 3.82 (1H, d, J = 16.0 Hz), 4.31 (2H, q, J = 7.1 
Hz), 5.53 (1H, s), 7.13 - 7.79 (13H, m) 
 
13C-NMR (CDCl3) δ 14.2 (q), 29.9 (q), 34.6 (t), 44.2 (t), 60.3 (d), 62.0 
(t), 76.4 (d), 81.2 (s), 114.0 (s), 119.7 (dd, J2C-F = 
23.2 Hz), 120.2 (dd, J3C-F = 7.4 Hz),  125.6 (dd, J
2
C-
F = 21.8 Hz), 126.4 (d), 127.1 (s), 128.1 (d), 129.2 
(d), 129.4 (d), 129.8 (d), 130.2 (d), 130.3 (d), 135.4 
(s), 137.6 (s), 137.9 (s), 142.1 (s), 157.8 (d, J1C-F = 























R  = H, iPr, iBu, Bn, Me
R' = Cyclohexyl, Cyclopentyln Me
PG = Boc, Cbz, F moc, CO2Et  
To a solution of N-protected amino acid (10 mmol) in CH2Cl2 (60 mL) cooled at 
0° C were slowly added DCC (2.6 g, 10 mmol), the ap propriate N-allylamine (8.3 
mmol) and DMAP (0.015 g, 0.125 mmol). The resulting solution reacted at r.t. for 
48 h, then was filtered on silica gel (EdP/ AcOEt 7:3) and the solvent was 
evaporated under reduced pressure. The crude residue was purified by silica gel 




























Yield: 87 %  
Yellow oil  
IR: 1710, 1640 cm-1 
Rotamer ratio: 7/4 
 
Major Rotamer 
1H-NMR (CDCl3) δ 1.16-1.85 (10H, m), 1.44 (9H, s), 3.11-3.13 (1H, m), 
3.74-3.84 (2H, m), 4.41 (2H, m), 4.97-5.12 (2H, m), 
5.22 (1H, d, J = 7.7 Hz), 5.68-5.76 (1H, m) 
 
13C-NMR (CDCl3) δ 25.2 (t), 25.7 (t), 26.2 (t), 28.3 (q), 30.5 (t), 31.8 (t), 
45.0 (t), 45.8 (t), 54.3 (d), 84.6 (s), 116.7 (t), 134.6 
(d), 155.8 (s), 172.8 (s). 
 
Minor rotamer  
1H-NMR (CDCl3) δ 1.16-1.85 (10H, m), 1.44 (9H, s), 3.58-3.60 (1H, m), 
3.74-3.84 (2H, m), 4.41 (2H, m), 4.97-5.12 (2H, m), 
5.16 (1H, d, J = 7.6 Hz), 5.68-5.76 (1H, m) 
 
13C-NMR (CDCl3) δ 25.2 (t), 25.7 (t), 26.2 (t), 27.9 (q), 30.7 (t), 31.6 (t), 
44.8 (t), 45.5 (t), 54.1 (d), 83.8 (s), 115.9 (t), 135.0 















Yield: 82 %   
Yellow oil 
Rotamer ratio: 5/4 
 
Major Rotamer  
1H-NMR (CDCl3)  δ 1.24-1.81 (10H, m,), 3.93 (2H, d, J = 5.1 Hz), 3.99 
(2H, d, J = 4.2 Hz), 4.37-4.39 (1H, m), 5.09-5.23 
(4H, m), 5.73-5.83 (1H, m), 5.91 (1H, d), 7.27-7.38 
(5H, m) 
 
13C-NMR (CDCl3)            δ 25.5 (t), 25.7 (t), 26.1 (t), 30.5 (t), 31.7 (t), 43.1 (t), 
44.8 (t), 56.3 (d), 66.8 (s), 116.2 (t), 127.0 (d), 
127.6 (d), 128.1 (d), 128.5 (d), 128.8 (d), 134.3 (d), 
136.5 (s), 156.2 (s), 168.2 (s). 
 
Minor rotamer  
1H-NMR (CDCl3) δ 1.24-1.81 (10H, m),  3.43-4.45 (1H, m), 3.82 (2H, 
d, J = 5.1 Hz), 4.08 (2H, d, J = 4.2 Hz), 5.09-5.23 
(4H, m), 5.57 (1H, m), 5.73-5.83 (1H, m), 7.27-7.38 
(5H, m) 
 
13C-NMR (CDCl3)           δ 25.5 (t), 25.7 (t), 26.1 (t), 30.7 (t), 31.7 (t), 42.9 (t), 
44.4 (t), 54.3 (d), 67.1 (t), 117.0 (t), 127.0 (d), 127.6 
(d), 128.1 (d), 128.5 (d), 128.8 (d), 134.8 (d), 136.5 

















Colorless oil  
IR: 1712, 1640 cm-1;  
Mixture of two rotamers with distinguishable peaks solely in the 13C NMR 
spectrum; 
 
1H NMR (CDCl3) δ 1.01 – 1.83 (10H, m), 3.72 – 3.76 (1H, m), 3.87 – 
3.90 (1H, m), 3.96 – 3.99 (1H, m), 4.03 – 4.09 (2H, 
m), 4.16– 4.22 (1H, m), 4.30 – 4.35 (2H, m), 5.07 – 
5.19 (2H, m), 5.60 – 5.86 (1H, m), 6.00 – 6.10 (1H, 
m), 7.26 (2H, dd, J = 7.4, 7.3 Hz), 7.34 (2H, dd, J = 
7.4, 7.3 Hz), 7.59 (2H, d, J = 7.3 Hz), 7.70 (2H, d, J 
=7.4 Hz) 
 
 13C NMR (CDCl3) δ 25.1 (t), 25.4 (t), 25.7 (t), 30.5 (t), 31.6 (t), 42.8 (t), 
43.1 (t,rotamer peak), 44.4 (t), 44.9 (t, rotamer 
peak), 47.1 (d), 54.4 (d), 56.3 (d, rotamer peak), 
67.1 (t), 116.2(t), 116.8 (t, rotamer peak), 119.9 (d), 
125.2 (d), 127.0 (d), 127.6 (d), 134.4 (d), 134.9 (d, 
rotamer peak),141.2 (s), 144.0 (s), 156.3 (s), 167.1 





















IR: 1708, 1642 cm-1 
Mixture of two rotamers with distinguishable peaks solely in the 13C NMR 
spectrum 
 
1H NMR (CDCl3) δ 0.75 – 1.98 (13H, m), 3.75 – 4.40 (7H, m), 4.98 – 
5.19 (2H, m), 5.66 - 5.76 (2H, m)  
 
13C NMR(CDCl3) δ 14.5 (q), 25.1 (t), 25.2 (t), 25.4 (t), 30.5 (t), 31.6 (t), 
42.9 (t), 43.0 (t, rotamer peak), 44.3 (t), 44.9 (t, 
rotamer peak), 54.2 (d), 56.3 (d, rotamer peak), 
60.9 (t), 116.1 (t), 116.8 (t, rotamer peak), 134.4 
(d), 134.8 (d, rotamer peak), 156.5 (s), 167.3 (s), 


























Yield: 72 %  
Colourless oil 
IR: l1635, 1709 cm-1 
[α d ]D25: +74.9 (c=2.620 g/L,  CHCl3) 
Rotamer ratio: 6:1 
 
Major Rotamer 
1H-NMR (CDCl3)  δ 0.89-0.93 (6H, m), 1.08-1.96 (11H, m), 1.44 (9H, s), 
3.75-4.16 (2H, m), 4.29-4.35 (1H, m), 4.50-4.51 
(1H, m), 5.08-5.26 (2H, m), 5.29-5.31 (1H, m), 
5.78-5.84 (1H, m) 
 
13C-NMR (CDCl3)            δ 17.3 (q), 20.0 (q), 25.7 (t), 26.0 (t), 26.2 (t), 28.5 
(q), 30.5 (t), 31.9 (d), 32.1 (t), 44.4 (t), 54.3 (d), 57.4 





1H-NMR (CDCl3) δ 0.98-1.00 (6H, m), 1.08-1.96 (11H, m), 1.44 (9H, s), 
3.75-4.16 (2H, m), 4.29-4.35 (1H, m), 4.50-4.51 
(1H, m), 5.08-5.26 (2H, m), 5.29-5.31 (1H, m), 
5.78-5.84 (1H, m) 
13C-NMR (CDCl3)           δ 17.8 (q), 19.8 (q), 25.4 (t), 26.0 (t), 26.2 (t), 28.5 
(q), 31.0 (t), 32.3 (t), 32.4 (d), 45.9 (t), 53.7 (d), 56.0 













Yield: 70 %  
White solid  
[α d ]D25: +2.4  (c=3.710 g/L in CHCl3) 




1H-NMR (CDCl3) δ 0.84-0.96 (6H, m), 1.53-1.95 (9H, m), 1.41 (9H, s), 
3.67-4.03 (2H, m), 4.24-4.30 (2H, m), 5.06-5.11 
(2H, m), 5.18-5.21 (1H, m), 5.78-5.85 (1H, m) 
 
13C-NMR (CDCl3)            δ 17.1 (q), 19.6 (q), 23.9 (t), 25.7 (t), 28.3 (q), 29.3 (t), 
29.8 (t), 32.0 (d), 44.2 (t), 55.1 (d), 58.6 (d), 78.2 
(s), 115.5 (t), 134.8 (d), 155.5 (s), 172.5 (s). 
 
Minor rotamer  
 
1H-NMR (CDCl3) δ 0.84-0.96 (6H, m), 1.53-1.95 (9H, m), 1.41 (9H, s), 
3.67-4.03 (2H, m), 4.55 (1H, dd, J = 5.7, 9.2 Hz), 
4.61-4.66 (1H, m), 5.06-5.11 (2H, m), 5.29-5.34 
(1H, m), 5.78-5.85 (1H, m) 
 
13C-NMR (CDCl3)           δ 17.5 (q), 19.8 (q), 23.9 (t), 25.7 (t), 28.3 (q), 29.3 (t), 
30.2 (t), 32.2 (d), 46.4 (t), 55.9 (d), 56.3 (d), 78.2 












Yield: 87 % 
Yellow oil 
IR: 1639,1709 cm-1 
[α d ]D25: -1.2  (c=1.940g/L,  CHCl3) 
Rotamer ratio: 3:2 
 
Major Rotamer 
1H-NMR (CDCl3)  δ 0.78-0.92 (6H, m), 1.21-1.26 (3H, m), 1.30 (9H, s), 
1.30-1.40 (3H, m), 1.54-1.66 (7H, m), 3.52-3.58 
(1H, m), 3.68-4.02 (2H, m), 4.54-4.58 (1H, m), 
4.92-5.12 (2H, m), 5.27-5.29 (1H, m), 5.63-5.78 
(1H, m) 
  
13C-NMR (CDCl3) δ 22.1 (q), 23.8 (q), 24.9 (d), 25.7 (t), 26.0 (t), 26.3 
(t), 28.6 (q), 30.7 (t), 31.8 (t), 43.9 (t), 44.4 (t), 49.2 
(d), 57.2 (d), 79.4 (s), 115.9 (t), 135.5 (d), 155.7 (s), 
172.5 (s). 
 
Minor rotamer  
1H-NMR (CDCl3) δ 0.78-0.92 (6H, m), 1.21-1.26 (3H, m), 1.30 (9H, s), 
1.30-1.40 (3H, m), 1.54-1.66 (7H, m), 4.20-4.22 
(1H, m),  3.68-4.02 (2H, m), 4.36-4.40 (1H, m), 




13C-NMR (CDCl3) δ 22.0 (q), 23.7 (q), 24.9 (d), 25.5 (t), 26.1 (t), 26.3 
(t), 28.6 (q), 30.9 (t), 32.4 (t), 43.3 (t), 45.6 (t), 49.6 









Yield: 80 %  
Yellow oil 




1H-NMR (CDCl3) δ 0.85-0.99 (6H, m), 1.20-1.25 (3H, m), 1.43 (9H, s), 
1.31-1.69 (8H, m), 3.67-3.82 (2H, m), 4.39-4.48 
(2H, m), 5.07-5.18 (2H, m), 5.22-5.24 (1H, m), 
5.83-5.87 (1H, m) 
13C-NMR (CDCl3) δ 21.8 (q), 23.7 (q), 24.6 (d), 25.5 (t), 26.0 (t), 28.3 
(q), 29.2 (t), 30.2 (t), 31.5 (t), 43.7 (t), 51.7 (d), 58.3 




1H-NMR (CDCl3) δ 0.85-0.99 (6H, m), 1.20-1.25 (3H, m), 1.43 (9H, s), 
1.31-1.69 (8H, m), 3.67-3.82 (2H, m), 4.69-4.76 
(2H, m), 5.07-5.18 (2H, m), 5.30-5.32 (1H, m), 
5.83-5.87 (1H, m) 
 
13C-NMR (CDCl3) δ 21.8 (q), 23.7 (q), 24.7 (d), 25.3 (t), 25.9 (t), 28.3 
(q), 29.1 (t), 29.7 (t), 31.7 (t), 44.2 (t), 50.0 (d), 56.0 














Yield: 61 % 
Colorless oil 
[α d ]D25: +2.6  (c=1.229 g/L, CHCl3) 
Rotamer ratio: 5:4 
 
Major rotamer  
1H-NMR (CDCl3) δ 1.15-1.93 (10H, m), 1.36 (9H, s), 2,91-2,97 (2H, m), 
3.33-3.38 (2H, m), 3.62-3.66 (1H, m), 4.60 (1H, dd, 
J = 7.9, 15.0 Hz), 5.00-5.06 (2H, m), 5.33 (1H, d, J 
= 8.2 Hz), 5.54-5.61 (1H, m), 7.18- 7.28 (5H, m) 
 
13C-NMR (CDCl3)           δ   25.6 (t), 25.8 (t), 26.2 (t), 28.7(q), 30,7 (t), 31.7 (t), 
40.8 (t), 44.7 (t), 52.8 (d),54.3 (d), 79.7 (s), 116.7 
(t), 127,1 (d) 127.7 (d), 128.8 (d), 129.0 (d), 130.0 
(d), 135.4 (d), 137.2 (s), 155.2 (s), 171.5 (s)  
 
Minor rotamer 
1H-NMR (CDCl3)             δ 1.15-1.93 (10H, m), 1.36 (9H, s), 2,91-2,97 (2H, m), 
3.62-3.66 (1H, m), 3.90 (1H, dd, J = 5.4, 15.4 Hz), 
4.27-4.32 (1H, m), 4.85 (1H, dd, J = 8.0, 14.7 Hz), 
5.00-5.06 (2H, m), 5.46 (1H, d, J = 8.1 Hz), 5.65-
5.73 (1H, m), 7.18- 7.28 (5H, m),  
 
13C-NMR (CDCl3)          δ   25.6 (t), 25.8 (t), 26.2 (t), 28.7(q), 30,7 (t), 32.4 (t), 
40.8 (t), 45.3 (t), 51.8 (d),57.7 (d), 79.7 (s), 116.3 
(t), 127,1 (d) 128.7 (d), 128.8 (d), 129.0 (d), 130.0 









Yield: 90 %  
Colorless oil  
[α d ]D25: +9.2  (c=3.760 g/L, CHCl3) 
Rotamer ratio: 5/4  
 
Major rotamer 
1H-NMR (CDCl3) δ 1.16-1.76 (8H, m), 1.40 (9H, s), 2,93-2,98 (2H, m), 
3.31-3.36 (1H, m), 3.53-3.57 (1H, m), 4.01-4.04 
(1H, m), 4.59-4.61 (1H, m), 5.00-5.12 (2H, m), 5.31 
(1H, d, J = 8.5 Hz), 5.63-5.69 (1H, m), 7.17-7.33 
(5H, m) 
 
13C-NMR (CDCl3) δ  23.4 (t), 23.8 (t), 28.3(q), 30,0 (t), 31.4 (t), 40.6 (t), 
44.4 (t), 52.6 (d), 58.7 (d), 79.4 (s), 116.2 (t), 126.7 
(d), 128.4 (d), 128.7 (d), 129.2 (d), 129.6 (d), 134.6 
(d), 137.7 (s), 153.3 (s), 172.7 (s)  
 
Minor rotamer 
1H-NMR (CDCl3) δ 1.16-1.76 (8H, m), 1.40 (9H, s), 2,93-2,98 (2H, m), 
3.65-3.70 (1H, m), 3.88-3.92 (1H, m), 4.71-4.74 
(1H, m), 4.95-4.98 (1H, m), 5.00-5.12 (2H, m), 5.41 
(1H, d, J = 8.6 Hz), 5.73-5.77 (1H, m), 7.17-7.33 
(5H, m),   
 
13C-NMR (CDCl3)          δ   23.4 (t), 23.9 (t), 28.2(q), 29.3 (t), 32.5 (t), 
40.5 (t), 45.2 (t), 51.4 (d), 55.7 (d), 80.3 (s), 
115.8 (t), 126.8 (d), 128.4 (d), 128.7 (d), 
 108
129.2 (d), 129.6 (d), 134.7 (d), 137.6 (s), 
154.8 (s), 173.2 (s)  
 






Yield: 77 %  
Yellow oil 
[α d ]D25: -0.9  (c=3.470 g/L, CHCl3)  
IR: 1641, 1709 cm-1 




1H-NMR (CDCl3) δ 1.25-1.29 (3H, m), 1.37-1.80 (10H, m), 1.45 (9H, s), 
3.82-4.16 (2H, m), 4.35 (1H, s br), 4.65-4.67 (1H, 
m), 5.08-5.15 (2H, m), 5.62-5.63 (1H, m), 5.77-5.86 
(1H, m) 
13C-NMR (CDCl3)           δ   19.6 (q), 25.3 (t), 25.5 (t), 25.9 (t), 28.3 (q), 30.6 (t), 
31.9 (t), 45.4 (t), 46.5 (d), 54.0 (d), 78.9 (s), 116.3 
(t), 135.7 (d), 155.0 (s), 171.8 (s). 
 
Minor rotamer 
1H-NMR (CDCl3)             δ 1.32-1.35 (3H, m), 1.37-1.80 (10H, m), 1.45 (9H, s), 
3.82-4.16 (2H, m), 4.35 (1H, s br), 4.48-4.52 (1H, 
m), 5.20-5.24 (2H, m), 5.32-5.34 (1H, m), 5.77-5.86 
(1H, m) 
13C-NMR (CDCl3)          δ   19.3 (q), 25.3 (t), 25.5 (t), 25.9 (t), 28.3 (q), 30.4 (t), 
32.1 (t), 44.2 (t), 46.7 (d), 56.8 (d), 78.9 (s), 115.5 










Yield: 70 % 
Colorless oil  
[α d ]D25: -9.6 (c=3.210 g/L, CHCl3) 
Rotamer ratio: 6/4  
 
Major rotamer 
1H-NMR (CDCl3)             δ 0.86-0.90 (3H, m), 1.07 (9H, s), 1.21-1.48 (8H, m), 
3.46-3.50 (1H, m), 3.73-3.77 (1H, m), 3.90-3.95 
(1H, m), 4.09-4.14 (1H, m), 4.71-4.86 (2H, m), 
5.34-5.52 (2H, m) 
 
13C-NMR (CDCl3)           δ   19.5 (q), 23.4 (t), 23.6 (t), 27.4 (q), 28.8 (t), 29.8 (t), 
45.7 (t), 48.7 (d), 58.0 (d), 78.7 (s), 114.9 (t), 134.8 
(d), 154.8 (s), 172.0 (s). 
 
Minor rotamer  
1H-NMR (CDCl3) δ 0.97-1.01 (3H, m), 1.07 (9H, s), 1.21-1.48 (8H, m), 
3.57-3.61 (1H, m), 3.73-3.77 (1H, m), 4.31-4.38 
(2H, m), 4.71-4.86 (2H, m), 5.34-5.52 (2H, m) 
 
13C-NMR (CDCl3) δ 19.1 (q), 23.4 (t), 23.5 (t), 27.4 (q), 28.6 (t), 29.4 (t), 
45.8 (t), 49.8 (d), 55.9 (d), 78.7 (s), 115.9 (t), 134.5 








Synthesis of hydroamination Product (53)  
7-Cyclohexyldihydro-1 H-oxazolo[3,4-a]pyrazine-3,6(5 H,7H)-dione from glycine 














DMF, 100 °C, 24h
a: R = Cbz
b: R = Fmoc
c: R = CO2Et  
 
The allylamide of a nitrogen protected glycine 54a-c (1 mmol) was disolved in 10 
mL of DMF. CuCl2 (3 mmol) and Pd(CH3CN)2Cl2 (0.05 mmol) were added. The 
reaction mixture was left under agitation at 100°C for 24 hours. Brine was added 
to the reaction mixture and it was extracted with CH2Cl2 (3x 10 ml).  The organic 
phase was dried with Na2SO4 and the solvent is evaporated at reduced pressure. 
The obtained crude was purified by a column chromatography ( EdP / AcOEt 8:2) 
. 
Yield: 81 %  
Yellow solid 
M.p.: 118-124 °C 
IR:  1630, 1751 cm-1 
1H-NMR (CDCl3)  δ 1.00-1.95 (10H, m),  3.26 (1H, dd, J = 12.1, 10.9 
Hz), 3.39 (1H, dd, J = 12.1, 4.0 Hz), 3.89 (1H, A 
part of AB system, J = 14.0 Hz), 3.98-4.05 (1H, m), 
4.11 (1H, dd, J = 3.48, 9.12 Hz), 4.36 (1H, B part of 
AB system, J = 14.0 Hz), 4.48-4.52 (2H, m) 
 
13C-NMR (CDCl3) δ 25.3 (t), 25.4 (t), 25.5 (t), 29.3 (t), 29.7 (t), 44.2 (t), 




























5755 a-h  
Boc CuCl2 (3 equiv)
PdCl2(MeCN)2  (5% mol)
DMF; 24 h, 100 °C
 
CuCl2 98 % (1 eq.) and Pd(CH3CN)2Cl2 99 % (0,05 eq.) were dissolved in dry  
DMF (10 mL). The allylaminoamide 55 a-h (1 eq.) dissolved in dry DMF (10 mL) 
was added, the reaction mixture was left under agitation at 100 °C for 24 ore. 
Brine was added to the reaction mixture and it was extracted 3 times with 
CH2Cl2.  The organic phase was dried with Na2SO4 and the solvent is evaporated 
at reduced pressure. The obtained crude was purified by a column 



























Yield: 48 %  
Red solid   
M.p.: 116-120 °C  
[α d ]D 25= +20.4  (c=1.730g/L,  CHCl3) 
 
1H-NMR (CDCl3) δ 0.84 (3H, d, J = 6.8 Hz), 0.99 (3H, dd, J = 6.8, 1.2 
Hz), 1.15-1.80 (10H, m), 2.57-2.70 (1H, m), 3.19 
(1H, dd, J = 11.9, 11.3 Hz), 3.30 (1H, dd, J = 11.9, 
4.2 Hz), 3.97-4.06 (2H, m), 4.15 (1H, s br), 4.40-
4.53 (2H, m) 
 
13C-NMR (CDCl3) δ 17.8 (q), 19.5 (q), 25.3 (t), 25.5 (t), 29.4 (t), 29.6 (t), 
32.3 (d), 44.4 (t), 51.2 (d), 52.7 (d), 60.6 (d), 64.8 

























Yield: 18 % 
Red Solid   
M.p.: 134-139 °C  
[α d ]D25: -57.8  (c=1.540g/L,  CHCl3) 
 
1H-NMR (CDCl3) δ 0.88 (3H, d, J = 7.4 Hz), 1.01-1.90 (10H, m), 1.17 
(3H, d, J = 7.4 Hz), 2.86 (1H, dqq, J = 7.4, 7.4, 3.9 
Hz), 3.20 (1H, dd, J = 12.0, 9.9 Hz), 3.45 (1H, dd, J 
= 12.0, 2.6 Hz), 3.88-3.98 (2H, m), 4.11 (1H, d, J = 
2.6 Hz), 4.43-4.49 (2H, m)  
 
13C-NMR (CDCl3) δ 16.1 (q), 19.8 (q), 25.2 (t), 25.4 (t), 25.6 (t), 29.1 (t), 
29.5 (d), 30.3 (t), 43.6 (t), 53.0 (d), 53.2 (d), 62.2 





















Yield: 56 %  
Red Solid   
M.p.:  139-142 °C   
[α d ]D25: +66.9  (c=1.050g/L,  CHCl3) 
 
1H-NMR (CDCl3) δ 0.89 (3H, d, J = 7.0 Hz), 1.04 (3H, d, J = 7.0 Hz), 
1.30-1.88 (8H, m), 2.66 (1H, dqq, J = 7.0, 7.0, 3.2 
Hz), 3.21-3.31(2H, m), 3.99-4.05 (1H, m), 4.08 (1H, 
dd, J = 9.2, 1.6 Hz), 4.17 (1H, d, J = 3.2 Hz), 4.44-
4.49 (1H, m), 4.95-5.01 (1H, m)  
 
13C-NMR (CDCl3) δ 17.8 (q), 19.5 (q), 23.9 (t), 24.2 (t), 27.4 (t), 28.7 (t), 
32.3 (d), 44.6 (t), 51.2 (d), 54.6 (d), 60.7 (d), 64.8 
























Yield: 23 %  
Yellow solid 
M.p.: 117-120 °C   
[α d ]D25 = -13.8    (c=1.420g/L, CHCl3) 
 
1H-NMR (CDCl3) δ 0.89 (3H, d, J = 7.0 Hz), 1.17 (3H, d, J = 7.0 Hz), 
1.25-1.95 (8H, m), 2.85 (1H, ddq, J = 7.0, 7.0, 3.0 
Hz), 3.27 (1H, dd, J = 12.0, 10.0 Hz), 3.36 (1H, dd, 
J = 12.0, 2.6 Hz), 3.95-3.98 (2H, m), 4.12 (1H, d, J 
= 3.0 Hz), 4.44-4.47 (1H, m), 4.90-4.99 (1H, m)  
 
13C-NMR (CDCl3) δ 16.1 (q), 19.8 (q), 24.0 (t), 24.1 (t)(, 28.2 (t), 28.3 
(t), 29.3 (d), 43.8 (t), 53.1 (d), 54.6 (d), 62.4 (d), 





























Yield: 62 %   
Yellow Solid    
M.p.: 117-119 °C    
[α d ]D25: +18.8 (c=2.200g/L, CHCl3) 
 
1H-NMR (CDCl3) δ 0.91 (3H, d, J = 6.4 Hz), 0.99 (3H, d, J = 6.4 Hz), 
1.25-1.85 (13H, m), 3.23 (1H, dd, J = 11.9, 10.9 
Hz), 3.31 (1H, dd, J = 11.9, 4.5 Hz), 3.99-4.02 (1H, 
m), 4.07 (1H, dd, J = 9.2, 6.0 Hz), 4.32 (1H, dd, J = 
10.4, 3.6 Hz), 4.40-4.46 (2H, m)  
 
13C-NMR (CDCl3)            δ 21.2 (q), 23.3 (q), 24.7 (d), 25.4 (t), 25.5 (t), 29.4 
(t), 29.5 (t), 41.6 (t), 44.4 (t), 48.2 (d), 52.7 (d), 53.9 


























Yield: 9 % 
Orange solid   
M.p.: 133-136 °C  
[α d ]D25: -36.5  (c=2.230 g/L,  CHCl3)  
 
1H-NMR (CDCl3) δ 0.80-1.02 (6H, m), 1.05-2.16 (13, m), 3.22 (1H, dd, 
J = 12.0, 10.0 Hz), 3.48 (1H, dd, J = 12.0, 2.3 Hz), 
3.92-3.97 (2H, m), 4.17-4.21 (1H, m), 4.40-4.48 
(2H, m) 
 
13C-NMR (CDCl3) δ 22.2 (q), 23.7 (q), 24.5 (d), 25.3 (t), 25.4 (t), 25.5 
(t), 29.2 (t), 29.7 (t), 39.3 (t), 43.8 (t), 53.0 (d), 53.1 


























Yield: 62 %  
M.p.: 118-121 °C  
[α d ]D25: +29.3  (c=2.360 g/L, CHCl3) 
 
1H-NMR (CDCl3) δ 0.92 (3H, d, J = 6.5 Hz), 0.99 (3H, d, J = 6.5 Hz), 
1.31-1.87 (11H, m). 3.22-3.32 (2H, m), 3.99-4.05 
(1H, m), 4.09 (1H, dd, J = 9.2, 1.5 Hz), 4.31 (1H, 
dd, J = 10.7, 3.0 Hz), 4.42 (1H, dd, J = 9.2, 8.2 Hz), 
4.90-4.96 (1H, m)  
 
13C-NMR (CDCl3)            δ 21.2 (q), 23.4 (q), 23.9 (t), 24.2 (t), 24.7 (d), 27.4 
(t), 28.4 (t), 41.7 (t), 44.4 (t), 48.2 (d), 53.9 (d), 54.6 
























Yield: 15 %  
Brown solid   
M.p.: 100-102 °C  
[αd]D25: -8.3  (c=1.720 g/L, CHCl3) 
 
1H-NMR (CDCl3) δ 0.85-1.00 (6H, m), 1.20-2.17 (11H, m), 3.28 (1H, 
dd, J = 12.0, 9.4 Hz), 3.40 (1H, dd, J = 12.0, 1.2 
Hz), 3.94-4.09 (2H, m), 4.20 (1H, dd, J = 7.1, 3.5 
Hz), 4.48 (1H, s br), 4.91-4.99 (1H, m) 
 
13C-NMR (CDCl3)            δ 22.0 (q), 23.7 (q), 24.0 (t), 24.2 (t), 24.4 (d), 27.8 
(t), 28.3 (t), 39.3 (t), 44.0 (t), 53.0 (d), 54.7 (d), 56.4 


























Yield: 57 % 
Yellow solid    
M.p.: 168-171 °C  
[α d ]D25: -6.6  (c=1.760 g/L, CHCl3) 
 
1H-NMR (CDCl3) δ 0.82-1.79 (10H, m), 2.75-2.83 (1H, m), 3.01-3.08 
(3H, m), 3.57 (1H, dd, J = 13.4, 3.5 Hz), 3.85 (1H, 
dd, J = 8.9, 3.6 Hz), 4.17 (1H, dd, J = 8.9, 8.4 Hz), 
4.47-4.58 (2H, m), 7.16-7.27 (5H, m) 
 
13C-NMR (CDCl3) δ 25.3 (t), 25.4 (t), 25.5 (t), 29.3 (t), 29.5 (t), 37.9 (t), 
44.7 (t), 49.5 (d), 52.9 (d), 55.8 (d), 65.0 (t), 127.1 

























Yellow solid    
Yield: 25 % 
M.p.: 139-142 °C   
[α d ]D25: -88.3 (c=2.050 g/L, CHCl3) 
1H-NMR (CDCl3) δ 0.80-1.80 (11H, m), 2.95 (1H, dd, J = 8.5, 3.5 Hz), 
3.24 (1H, dd, J = 13.6, 2.3 Hz), 3.64 (1H, dd, J = 
10.5, 8.5 Hz), 3.80-3.90 (2H, m), 4.32-4.52 (3H, m), 
7.16-7.27 (5H, m)  
 
13C-NMR (CDCl3) δ 25.2 (t), 25.3 (t), 25.5 (t), 29.3 (t), 29.4 (t), 35.2 (t), 
42.4 (t), 52.1 (d), 52.8 (d), 57.5 (d), 65.5 (t), 127.2 

























Yield: 41 %    
Yellow solid   
M.p.: 83-86 °C   
[α d ]D25: +10.1 (c=2.220 g/L, CHCl3) 
 
1H-NMR (CDCl3) δ 1.07-1.90 (8H, m), 2.78-2.82 (1H, m), 2.92-3.14 
(3H, m), 3.50 (1H, d, J = 13.1 Hz), 3.84 (1H, d, J = 
6.4 Hz), 4.11-4.15 (1H, m), 4.51 (1H, s br), 4.93-
4.99 (1H, m), 7.10-7.25 (5H, m) 
 
13C-NMR (CDCl3)  δ 23.9 (t), 24.2 (t), 27.3 (t), 28.5 (t), 38.0 (t), 44.8 (t), 
49.5 (d), 54.7 (d), 55.9 (d), 65.0 (t), 127.1 (d), 128.4 




















Yield: 13 % 
Orange solid   
M.p.: 158-161 °C  
[α d ]D25: -8.9   (c=2.570 g/L, CHCl3) 
 
1H-NMR (CDCl3) δ 0.95-1.95 (9H, m), 2.83 (1H, dd, J = 12.0, 3.2 Hz), 
3.22 (1H, dd, J = 9.6, 2.7 Hz), 3.64 (1H, dd, J = 
10.6, 8.4 Hz), 3.82-3.88 (2H, m), 4.35 (1H, dd, J = 
8.4, 7.8 Hz), 4.51 (1H, dd, J = 4.9, 2.7 Hz), 4.94-
4.99 (1H, m), 7.12-7.30 (5H, m)  
 
13C-NMR (CDCl3) δ 24.0 (t), 24.2 (t), 27.4 (t), 28.3 (t), 35.3 (t), 42.4 (t), 
51.9 (d), 54.2 (d), 57.6 (d), 65.6 (t), 127.2 (d), 128.2 

























Yield: 49 %   
Yellow solid   
M.p.: 116-122 °C   
[α d ]D25: +27.2  (c=3.110 g/L,  CHCl3) 
 
1H-NMR (CDCl3) δ 0.98-1.08 (1H, m), 1.20-1.45 (4H, m), 1.46 (3H, d, J 
= 7.1 Hz), 1.55-1.80 (5H, m), 3.22 (1H, dd, J = 
11.9, 10.6 Hz), 3.36 (1H, dd, J = 11.9, 3.9 Hz), 
3.99-4.08 (2H, m), 4.33 (1H,  J = 7.1 Hz), 4.40-4.96 
(2H, m) 
 
13C-NMR (CDCl3)            δ 18.3 (q), 25.4 (t), 25.5 (t), 29.2 (t), 29.4 (t), 29.6 (t), 
45.0 (t), 48.3 (t), 51.0 (d), 52.8 (d), 65.2 (t), 156.1 



























Yield: 55 %   
Red solid    
M.p.: 134-138 °C   
[α]D25 : +37.2  (c=1.640g/L, CHCl3) 
 
1H-NMR (CDCl3) δ 1.30-1.87 (8H, m), 1.46 (3H, d, J = 7.1 Hz), 3.29 
(2H, d, J = 7.0 Hz), 4.00-4.09 (2H, m), 4.35 (1H, q, 
J = 7.1 Hz), 4.43-4.48 (1H, dd, J = 8.6, 8.1 Hz), 
4.90-4.99 (1H, m) 
 
13C-NMR (CDCl3) δ 18.2 (q), 23.9 (t), 24.2 (t), 27.5 (t), 28.4 (t), 45.0 (t), 

































LiAlH4 (2.4 g, 63 mmol)  was dissolved in 60 mL of dry THF under nitrogen 
atmosphere, the mixture was cooled to 0°C and the a minoacid (2.0 g, 19 mmol) 
was added drop wise. Then the reaction mixture was heated to a 60°C. The 
reaction was monitored by TLC (BuOH / MeOH/ H2O/ AcOH 10:4.5:5:4). After 5 
hours 2 mL of H2O, 2 mL of NaOH al 15% were added and then other 6 mL of 
H2O. The reaction mixture was left under agitation all night. Then Na2SO4 was 
added untill the mixture became transparent and then it was filtered on celite. 
 
 















61a (R = H)




The aminoalcohol (50 mmol) was dissolved in dry THF (30-70 mL), TEA (2.95g, 
50 mmol) and then Boc2O (10.9 g, 50 mmol) were added. The reaction mixture 
was left under agitation at room temperature for 24 hours. The solvent was 
evaporated, 20 mL of H2O was added then it was extracted by AcOEt (40 mL x 





















61a, b 59a (R = H)





A solution of N-protected amino alcohol (1 mmol) in anhydrous THF (10 mL) was 
degassed (vacuum-N2 flush) and treated with allyl methyl carbonate (0.16g, 1.4 
mmol). A catalytic amount of tetrakis(triphenylphopshine)palladium (0.02 mol%) 
was added. The mixture was heated at 60° C for abou t 3 h. The THF was 
removed under reduced pressure. The residue was diluted with ethyl acetate and 
washed with aqueous saturated NaHCO3 solution. The organic layer was dried 
over Na2SO4, filtered and concentrated under vacuum. The residue was purified 






























IR: 1711 cm-1 
1H NMR (CDCl3)  δ 1.43 (9H, s), 3.28 – 3.31 (2H, m), 3.47 – 3.50 (2H, 
m), 3.94 – 3.98 (2H, m), 4.96 (1H, br s), 5.16 (1H, 
dd, J = 11.8, 1.2 Hz), 5.25 (1H, dd, J = 17.2, 1.2 
Hz), 5.83 – 5.92 (1H, m) 
 
13C-NMR (CDCl3) δ 28.3 (q), 40.4 (t), 69.1 (t), 71.9 (t), 79.5 (s), 117.1 














1H NMR (CDCl3)  δ 1.27 (6H, s), 1.40 (9H, s), 3.34 (2H, br s), 3.95 – 
3.99 (2H, m), 4.73 (1H, br s), 5.14 (1H, dd, J = 
10.4, 1.6 Hz), 5.23 (1H, dd, J = 17.2, 1.6 Hz), 5.83 
– 5.88 (1H, m) 
 
13C NMR (CDCl3) δ 24.2 (q), 28.4 (q), 52.6 (s), 72.2 (t), 76.4 (t), 79.8 






Cyclisation of Allylethers of N-Boc protected Aminoalcohols  











CH3CN, reflux, 3 h
Pd(CH3CN)2Cl2 (5 mol%)
59a (R= H) 60 a,b
59b (R= Me)  
The N-Boc protected allylether of the aminoalcohols 59a,b (1 mmol) were 
disolved in 10 mL of CH3CN,  CuCl2 (0.39g, 3 mmol) and Pd(CH3CN)2Cl2 (0.05 
mmol) were added. The mixture was left under reflux for 24 hours. Brine was 
added to the reaction mixture and it was extracted with CH2Cl2 (3x 10 ml).  The 
organic phase was dried with Na2SO4 and the solvent is evaporated at reduced 
pressure. The obtained crude was purified by a column chromatography (EdP/ 



























IR: 1745 cm-1 
1H-NMR (CDCl3)  δ 3.17-3.33 (2H, m), 3.45 (1H, ddd, J = 3.0, J = 11.8, 
J = 11.7), 3.72 (1H, dd, J = 3.0, J = 13.3), 3.87-3.97 
(4H, m),4.40 (1H, dd, J = 7.9, J = 8.0) 
 












Yield: 82 % 
Colorless oil 
IR: 1740 cm-1 
1H-NMR (CDCl3)  δ 1.32 (3H, s), 1.51 (3H, s),  3.16-3.26 (2H, m), 3.47 
(1H, d, J = 12.6), 3.68-3.72 (1H, m), 3.92-4.00 (1H, 
m), 4.04 (1H, dd, J = 3.6, J = 10.4), 4.29 (1H, dd, J 
= 7.7, J = 8.1) 
 
13C-NMR (CDCl3)  δ 20.5 (q), 22.5 (q), 50.8 (d), 53.1 (s), 63.9 (t), 70.1 
(t), 76.5 (t), 155.9 (s). 
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To a solution of glycinol (3.0 g, 49 mmol), DMAP (598 mg, 4.9 mmol) and TEA 
(9.9 g, 98 mmol) in CH2Cl2 (100 mL) at 0°C, TsCl (9.8 g, 51.5 mmol) was added 
drop by drop in CH2Cl2 (100 mL). The reaction mixture was left under agitation at 
room temperature for one night. Then the mixture was washed by H2O (50 mL x 
3) and then by brine (50 mL x 1). The organic phase was dried with Na2SO4, 
filtered and evaporated. 
Yield: 97%  
White solid 
M.p. 53-55°C 
Product is already reported.48 
 














A mixture of N-tosyl-glycinol 63 (4.9 g, 23 mmol), TBDMSCl (6.9 g, 46 mmol) 
and imidazole (3.1 g, 46 mmol) in DMF (40 mL) were left under agitation at room 
temerature for one night. Brine (40 mL) was then added and extracted with Et2O 
(40 mL x 3). The organic phase was dried with Na2SO4, filtered and evaporated. 
The crude was purified by coloumn chromatography. 
Colorless oil 
Yield: 98% 
















64 65  
 
To a suspention of NaH (432 mg, 18 mmol) in THF/DMF 4:1 (20 mL) at 0°C 
and under nitrogen atmosphere KI (3.0 g, 18 mmol) was  added and then a 
solution of N-tosil-O-tert-butyldimethylsilyl-glycinol 64 (3.9 g, 12 mmol) in 
THF/DMF 4:1 (20 mL) was added drop by drop. The mixture was left under 
agitation at room temperature at 0°C for 30 minutes . A solution of allylbromide 
(2.2 g, 18 mmol) in THF/DMF 4:1 (20 mL) was added drop by drop at 0°C. The 
reaction mixture was then left at room temperature for one night. 1 mL of H2O 
was added, the solvent was then evaporated. 30 mL of brine was added and 
extracted by Et2O (20 mL x 3). The organic phase was dried with Na2SO4, filtered 




























1H-NMR (CDCl3)  δ 0.04 (6H, s), 0.87 (9H, s), 2.43 (3H, s), 3.22 (2H, t, 
J = 6.4), 3.73 (2H, t, J = 6.4), 3.88 (2H, d, J = 6.4), 
5.14 (1H, dd, J = 1.3, J = 10.1), 5.17 (1H, dd, J = 
1.3, J = 17.1), 5.61-5.72 (1H, m), 7.28 (2H, d, J = 
7.9), 7.69 (2H, d, J = 7.9) 
 
13C-NMR (CDCl3)  δ 5.4 (q), 18.2 (s), 21.5 (q), 25.9 (q), 48.9 (t), 52.0 (t), 
62.3 (t), 118.8 (t), 127.2 (d), 129.6 (d), 133.3 (d), 
137.3 (s), 143.1 (s). 
 











The mixture of N-allyl-N-tosyl-O-tert-butyldimethylsilyl-glycinol 65 (3.3 g, 9 
mmol) and TBAF (2.8 g, 10.8 mmol) in THF were left under agitation at room 
temperature for 3 hours. The solvent was evaporated, H2O (30 mL) was added 
and it was extracted by CH2Cl2 (30 mL x 3). The organic phase was dried with 





Product is already reported50 
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The N-allyl-N-tosyl-glycinol 66 (1.3 g, 5 mmol) was dissolved in 60 mL of dry 
THF. Under nitrogen atmosphere Ph3P (2.6 g, 10 mmol), DIAD (2.0 g, 10 mmol) 
and DPPA (2.8 g, 10 mmol) were added. The reaction mixture was left under 
agitation at room temperature for 3 hours. The reaction mixture then was heated 
to 50°C for one hour. The solvent was evaporated an d the crude was purified by 
column chromatography. (EdP / AcOEt 85:15) 
Yield: 56% 
Colorless oil 
IR: 2104 cm-1 
 
1H-NMR (CDCl3)  δ 2.44 (3H, s), 3.26 (2H, t, J = 6.5), 3.47 (2H, t, J = 
6.5), 3.85 (2H, d, J = 6.5), 5.19 (1H, dd, J = 1.3, J = 
9.9), 5.20 (1H, dd, J = 1.3, J = 17.2), 5.58-5.75 (1H, 
m), 7.33 (2H, d, J = 8.2), 7.72 (2H, d, J = 8.2) 
 
13C-NMR (CDCl3)  δ 21.5 (q), 46.2 (t), 50.4 (t), 52.1 (t), 119.6 (t), 127.2 

























48 h  
 
The N-allyl-N-tosyl-2-azido ethylamine 67 (392 mg, 1.4 mmol) was dissolved in 
10 mL of dry THF and under nitrogen atmosphere at -20°C Me 3P (213 mg, 2.8 
mmol) and Boc-ON (382 mg, 1.5 mmol) were added. The mixture was left at -
20°C for 30 minutes and then at room temperature fo r 48 hours. 150 mL of 
CH2Cl2 were added and then it was washed by H2O (50 mL x 4) and brine (50 
mL x 1). The organic phase was dried with Na2SO4 filtered and evaporated. The 




1H-NMR (CDCl3)  δ 1.45 (9H, s), 2.44 (3H, s), 3.20 (2H, t, J = 5.8), 3.29 
(2H, t, J = 5.8), 3.81 (2H, d, J = 6.5), 5.95 (1H, br 
s), 5.17 (1H, dd, J = 1.3, J = 10.0), 5.19 (1H, dd, J 
= 1.3, J = 17.0), 5.51-5.68 (1H, m), 7.32 (2H, d, J = 
8.1), 7.70 (2H, d, J = 8.1) 
 
13C-NMR (CDCl3)  δ 21.9 (q), 28.4 (q), 46.9 (t), 51.7 (t), 65.9 (t), 79.5 (s), 
119.5 (t), 127.2 (d), 129.8 (d), 132.7 (d), 136.3 (s), 





























The N-allyl-N-tosyl-N’-tert-butoxycarbonyl ethelendiamine 68 (106 mg, 0.3 
mmol) was dissolved in 10 mL of CH3CN, CuCl2 (121 mg, 0.9 mmol) and 
Pd(CH3CN)2Cl2 (4 mg, 0.015 mmol) were added. The reaction mixture was left 
under reflux for 24 hours. 10 mL of brine were added and extracted by CH2Cl2 
(20 mL x 3). The organic phase was dried by Na2SO4, filtered and evaporated. 
The crude was purified by column chromatgraphy. (EdP / AcOEt 6:4) 
 





IR: 1738 cm-1 
1H-NMR (CDCl3)  δ 2.45 (3H, s), 3.16-3.25 (2H, m), 3.73 (1H, d, J = 
3.7), 3.76 (1H, d, J = 3.7), 3.84 (1H, d, J = 3.7), 
3.88 (1H, dd, J = 2.4, J = 3.7), 3.90-3.92 (1H, m), 
3.94-4.02 (1H, m), 4.42 (1H, dd, J = 8.4, J = 8.5), 
7.36 (2H, d, J = 8.2), 7.62 (2H, d, J = 8.2) 
 
13C-NMR (CDCl3)  δ 21.5 (q), 40.5 (t), 45.1 (t), 49.2 (t), 52.7 (d), 64.9 (t), 




























The  N-acetyl glycine (140 mg, 1.2 mmol) was dissolved in 20 mL of dry CH2Cl2, 
the mixture was cooled at 0° C. DCC (10 mmol), the appropriate N-allylamine 
(8.3 mmol) and DMAP (0.125 mmol) were slowly added. The resulting solution 
reacted at r.t. for 48 h, then was filtered on silica gel (EdP / AcOEt 7:3) and the 
solvent was evaporated under reduced pressure. The crude residue was purified 
by silica gel column (EdP / AcOEt 7:3) 
Yield : 82% 
Yellow oil 
IR: 1632,1740 cm-1 
Rotamer ratio 7/4 
 
Major Rotamer 
1H-NMR (CDCl3)  δ 0.91-1.95 (10H, m), 2.18 (3H, s), 3.11-3.15 (1H, m), 
3.74-3.81 (2H, m), 4.30-4.48 (2H, m), 4.97-5.10 
(2H, m), 5.20 (1H, d, J = 7.5), 5.68-5.75 (1H, m) 
 
13C-NMR (CDCl3)  δ 25.2 (t), 25.7 (t), 26.2 (t), 30.3 (q), 30.5 (t), 31.8 (t), 
45.0 (t), 45.8 (t), 54.2 (d), 116.7 (t), 134.6 (d), 155.8 
(s), 172.8 (s). 
 
Minor rotamer 
1H-NMR (CDCl3)  δ 0.91-1.95 (10H, m), 2.15 (3H, s), 3.58-3.60 (1H, m), 
3.74-3.80 (2H, m), 4.31-4.50 (2H, m), 4.97-5.10 
(2H, m), 5.11 (1H, d, J = 7.5), 5.69-5.76 (1H, m) 
 
13C-NMR (CDCl3)  δ 25.2 (t), 25.6 (t), 26.1 (t), 30.7 (q), 30.9 (t), 32.6 (t), 
44.8 (t), 45.5 (t), 54.1 (d), 115.9 (t), 135.0 (d), 153.8 
(s), 172.5 (s) 
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The 2-Acetamido-N-allyl-N-cyclohexylacetamide 68 (106 mg, 0.3 mmol) was 
dissolved in 10 mL of DMF, CuCl2 (121 mg, 0.9 mmol) e Pd(CH3CN)2Cl2 (4 mg, 
0.015 mmol) were added. The reaction mixture was left under reflux for 24 hours. 
10 mL of brine were added and extracted by CH2Cl2 (20 mL x 3). The organic 
phase was dried by Na2SO4, filtered and evaporated. The crude was purified by 




IR: 1684, 1707 cm-1  
 
1H-NMR (CDCl3)  δ 0.70-1.80 (10H, m), 2.03 (3H, d, J = 1.2), 2.18 (3H, 
s), 4.08 (2H, s), 4.21-4.38 (1H, m), 5.56 (1H, d, J = 
1.2) 
 
13C-NMR (CDCl3)  δ 17.5 (q), 25.3 (t), 25.6 (t), 28.2 (q), 30.9 (t), 48.6 (t), 
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